

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 188 822 A1

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:

20.03.2002 Bulletin 2002/12

(51) Int Cl.7: C12N 1/21, C12N 1/32,  
C12N 9/00, C12N 15/52,  
C12P 13/04

(21) Application number: 00915436.0

(86) International application number:  
PCT/JP00/02295

(22) Date of filing: 07.04.2000

(87) International publication number:  
WO 00/61723 (19.10.2000 Gazette 2000/42)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

- SUGIMOTO, Shinichi, Ajinomoto Co., Inc.  
Kawasaki-shi, Kanagawa 210-0801 (JP)
- TSUJIMOTO, Nobuharu, Ajinomoto Co., Inc.  
Kawasaki-shi, Kanagawa 210-0801 (JP)
- SHIMAOKA, Megumi, Ajinomoto Co., Inc.  
Kawasaki-shi, Kanagawa 210-0801 (JP)
- MIYATA, Yuri, Ajinomoto Co., Inc.  
Kawasaki-shi, Kanagawa 210-0801 (JP)
- OBA, Manami, Ajinomoto Co., Inc.  
Kawasaki-shi, Kanagawa 210-0801 (JP)

(30) Priority: 09.04.1999 JP 10314399

16.06.1999 JP 16944799

24.12.1999 JP 36809799

(71) Applicant: Ajinomoto Co., Inc.  
Tokyo 104-0031 (JP)(72) Inventors:  

- GUNJI, Yoshiya, Ajinomoto Co., Inc.  
Kawasaki-shi, Kanagawa 210-0801 (JP)
- YASUEDA, Hisashi, Ajinomoto Co., Inc.  
Kawasaki-shi, Kanagawa 210-0801 (JP)

(74) Representative: Strehl Schübel-Hopf & Partner  
Maximilianstrasse 54  
80538 München (DE)

## (54) L-AMINO ACID-PRODUCING BACTERIA AND PROCESS FOR PRODUCING L-AMINO ACID

(57) An L-amino acid is produced by culturing a *Methylophilus* bacterium which can grow by using methanol as a main carbon source and has L-amino acid-producing ability, for example, a *Methylophilus* bacterium in which dihydrodipicolinate synthase activity and aspartokinase activity are enhanced by transformation through introduction into cells, of a DNA coding for dihydrodipicolinate synthase that does not suffer feed-

back inhibition by L-lysine and a DNA coding for aspartokinase that does not suffer feedback inhibition by L-lysine, or a *Methylophilus* bacterium made to be casamino acid auxotrophic, in a medium containing methanol as a main carbon source, to produce and accumulate an L-amino acid in culture, and collecting the L-amino acid from the culture.

**Description**

**TECHNICAL FIELD**

5 [0001] The present invention relates to techniques in the field of microbial industry. In particular, the present invention relates to a method for producing an L-amino acid by fermentation, and a microorganism used in the method.

**BACKGROUND ART**

10 [0002] Amino acids such as L-lysine, L-glutamic acid, L-threonine, L-leucine, L-isoleucine, L-valine and L-phenylalanine are industrially produced by fermentation by using microorganisms that belong to the genus *Brevibacterium*, *Corynebacterium*, *Bacillus*, *Escherichia*, *Streptomyces*, *Pseudomonas*, *Arthrobacter*, *Serratia*, *Penicillium*, *Candida* or the like. In order to improve the productivity, strains isolated from nature or artificial mutants thereof have been used as these microorganisms. Various techniques have been disclosed for enhancing activities of L-glutamic acid biosynthetic enzymes by using recombinant DNA techniques, to increase the L-glutamic acid-producing ability.

15 [0003] The productivity of L-amino acids has been considerably increased by breeding of microorganisms such as those mentioned above and the improvement of production methods. However, in order to meet further increase in the demand in future, development of methods for more efficiently producing L-amino acids at lower cost have still been desired.

20 [0004] As methods for producing amino acids by fermentation of methanol which is a fermentation raw material available in a large amount at a low cost, there have conventionally known methods using microorganisms that belong to the genus *Achromobacter* or *Pseudomonas* (Japanese Patent Publication (Kokoku) No. 45-25273/1970), *Protaminobacter* or *Methanomonas* (Japanese Patent Application Laid-open (Kokai) No. 49-125590/1974), *Protaminobacter* or *Methanomonas* (Japanese Patent Application Laid-open (Kokai) No. 50-25790/1975), *Microcyclus* (Japanese Patent Application Laid-open (Kokai) No. 52-18886/1977), *Methylbacillus* (Japanese Patent Application Laid-open (Kokai) No. 4-91793/1992), *Bacillus* (Japanese Patent Application Laid-open (Kokai) No. 3-505284/1991) and so forth.

25 [0005] So far, however, no method has been known for producing L-amino acids by using *Methylophilus* bacteria. Although methods described in EP 0 035 831 A, EP 0 037 273 A and EP 0 066 994 A have been known as methods for transforming *Methylophilus* bacteria by using recombinant DNA, applying recombinant DNA techniques to improvement of amino acid productivity of *Methylophilus* bacteria has not been known.

**DISCLOSURE OF THE INVENTION**

30 [0006] The object of the present invention is to provide a novel L-amino acid-producing bacterium and a method for producing an L-amino acid by using the L-amino acid-producing bacterium.

35 [0007] As a result of the present inventors' efforts devoted to achieve the aforementioned object, they found that *Methylophilus* bacteria were suitable for producing L-amino acids. Further, although it has conventionally been considered difficult to obtain auxotrophic mutants of *Methylophilus* bacteria (FEMS Microbiology Rev. 39, 235-258 (1986) and Antonie van Leeuwenhoek 53, 47-53 (1987)), the present inventors have succeeded in obtaining auxotrophic 40 mutants of said bacteria. Thus, the present invention has been accomplished.

[0008] That is, the present invention provides the followings.

(1) A *Methylophilus* bacterium having L-amino acid-producing ability.  
45 (2) The *Methylophilus* bacterium according to (1), wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.

(3) The *Methylophilus* bacterium according to (1), which has resistance to an L-amino acid analogue or L-amino acid auxotrophy.

(4) The *Methylophilus* bacterium according to (1), wherein L-amino acid biosynthetic enzyme activity is enhanced.

50 (5) The *Methylophilus* bacterium according to (1), wherein dihydronicotinate synthase activity and aspartokinase activity are enhanced, and the bacterium has L-lysine-producing ability.

(6) The *Methylophilus* bacterium according to (1), wherein dihydronicotinate synthase activity is enhanced, and the bacterium has L-lysine-producing ability.

(7) The *Methylophilus* bacterium according to (1), wherein aspartokinase activity is enhanced, and the bacterium has L-lysine-producing ability.

55 (8) The *Methylophilus* bacterium according to any one of (5) to (7), wherein an activity or activities of one, two or three of enzymes selected from aspartic acid semialdehyde dehydrogenase, dihydronicotinate reductase and diaminopimelate decarboxylase is/are enhanced.

(9) The *Methylophilus* bacterium according to (5), wherein the dihydronicotinate synthase activity and the aspar-

EP 1 188 822 A1

tokinase activity are enhanced by transformation through introduction into cells, of a DNA coding for dihydriodicinate synthase that does not suffer feedback inhibition by L-lysine and a DNA coding for aspartokinase that does not suffer feedback inhibition by L-lysine.

5 (10) The bacterium according to (1), wherein activities of aspartokinase, homoserine dehydrogenase, homoserine kinase and threonine synthase, and the bacterium has L-threonine-producing ability.

(11) The bacterium according to any one of (1) to (10), wherein the *Methylophilus* bacterium is *Methylophilus methylotrophicus*.

10 (12) A method for producing an L-amino acid, which comprises culturing a *Methylophilus* bacterium as defined in any one of the above (1) to (11) in a medium to produce and accumulate an L-amino acid in culture and collecting the L-amino acid from the culture.

(13) The method according to (12), wherein the medium contains methanol as a main carbon source.

15 (14) A method for producing bacterial cells of a *Methylophilus* bacterium with an increased content of an L-amino acid, which comprises culturing a *Methylophilus* bacterium as defined in any one of the above (1) to (11) in a medium to produce and accumulate an L-amino acid in bacterial cells of the bacterium.

(15) The method for producing bacterial cells of the *Methylophilus* bacterium according to (14), wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.

20 (16) A DNA which codes for a protein defined in the following (A) or (B):

(A) a protein which has the amino acid sequence of SEQ ID NO: 6, or

25 (B) a protein which has an amino acid sequences of SEQ ID NO: 6 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has aspartokinase activity.

(17) The DNA according to (16), which is a DNA defined in the following (a) or (b):

30 (a) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5; or

(b) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5 or a part thereof under a stringent condition, and codes for a protein having aspartokinase activity.

35 (18) A DNA which codes for a protein defined in the following (C) or (D):

(C) a protein which has the amino acid sequence of SEQ ID NO: 8, or

(D) a protein which has an amino acid sequences of SEQ ID NO: 8 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has aspartic acid semialdehyde dehydrogenase activity.

(19) The DNA according to (18), which is a DNA defined in the following (c) or (d):

40 (c) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7; or

(d) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7 or a part thereof under a stringent condition, and codes for a protein having aspartic acid semialdehyde dehydrogenase activity.

45 (20) A DNA which codes for a protein defined in the following (E) or (F):

(E) a protein which has the amino acid sequence of SEQ ID NO: 10, or

50 (F) a protein which has an amino acid sequences of SEQ ID NO: 10 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydriodicinate synthase activity.

(21) The DNA according to (20), which is a DNA defined in the following (e) or (f):

55 (e) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 1268 to 2155 of SEQ ID NO: 9; or

(f) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 1268 to 2155 of SEQ ID NO: 9 or a part thereof under a stringent condition, and codes for a protein having dihydriodicinate synthase activity.

EP 1 188 822 A1

(22) A DNA which codes for a protein defined in the following (G) or (H):

- (G) a protein which has the amino acid sequence of SEQ ID NO: 12, or  
5 (H) a protein which has an amino acid sequences of SEQ ID NO: 12 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydridopicolinate reductase activity.

(23) The DNA according to (22), which is a DNA defined in the following (g) or (h):

- 10 (g) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11; or  
(h) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11 or a part thereof under a stringent condition, and codes for a protein having dihy-  
drodipicolinate reductase activity.

15 (24) A DNA which codes for a protein defined in the following (i) or (j):

- (i) a protein which has the amino acid sequence of SEQ ID NO: 14, or  
20 (j) a protein which has an amino acid sequences of SEQ ID NO: 14 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has diaminopimelate decarboxylase activity.

(25) The DNA according to (24), which is a DNA defined in the following (i) or (j):

- 25 (i) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13; or  
(j) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13 or a part thereof under a stringent condition, and codes for a protein having diami-  
nopimelate decarboxylase activity.

30 [0009] In the present specification, "L-amino acid-producing ability" refers to ability to accumulate a significant amount of an L-amino acid in a medium or to increase the amino acid content in the microbial cells when a microorganism of the present invention is cultured in the medium.

BRIEF DESCRIPTION OF THE DRAWINGS

35 [0010]

Fig. 1 shows the production process of plasmid RSF24P having a mutant *dapA*. The "*dapA\*24*" refers to a mutant *dapA* that codes for a mutant DDPS wherein the 118-histidine residue is replaced with a tyrosine residue.

40 Fig. 2 shows the production process of plasmid RSFD80 having a mutant *dapA* and a mutant *lysC*. The "*lysC\*80*" refers to a mutant *lysC* that codes for a mutant AKIII wherein the 352-threonine residue is replaced with an iso-  
leucine residue.

Fig. 3 shows aspartokinase activity of transformant *E. coli* strains containing an *ask* gene.

45 Fig. 4 shows aspartic acid semialdehyde dehydrogenase activity of transformant *E. coli* strains containing an *asd* gene.

Fig. 5 shows dihydridopicolinate synthase activity of transformant *E. coli* strains containing a *dapA* gene.

Fig. 6 shows dihydridopicolinate reductase activity of a transformant *E. coli* strain containing a *dapB* gene.

Fig. 7 shows diaminopimelate decarboxylase activity of transformant *E. coli* strains containing a *lysA* gene.

BEST MODE FOR CARRYING OUT THE INVENTION

50

<1> Microorganism of the present invention

[0011] The microorganism of the present invention is a bacterium belonging to the genus *Methylophilus* and having L-amino acid-producing ability. The *Methylophilus* bacterium of the present invention includes, for example, *Methylo-  
philus methylotrophicus* AS1 strain (NCIMB10515) and so forth. The *Methylophilus methylotrophicus* AS1 strain (NCIMB10515) is available from National Collections of Industrial and Marine Bacteria (Address: NCIMB Lts., Torry Research Station 135, Abbey Road, Aberdeen AB9 8DG, United Kingdom).

[0012] L-Amino acids produced according to the present invention include L-lysine, L-glutamic acid, L-threonine, L-

valine, L-leucine, L-isoleucine, L-tryptophan, L-phenylalanine, L-tyrosine and so forth. One or more types of such amino acids may be produced.

[0013] *Methylophilus* bacteria having L-amino acid-producing ability can be obtained by imparting L-amino acid-producing ability to wild strains of *Methylophilus* bacteria. In order to impart L-amino acid-producing ability, there can be used methods conventionally adopted for breeding coryneform bacteria, *Escherichia* bacteria or the like, such as those methods for obtaining auxotrophic mutant strains, strains resistant to L-amino acid analogues or metabolic control mutant strains, and methods for producing recombinant strains wherein L-amino acid biosynthetic enzyme activities are enhanced (see "Amino Acid Fermentation", the Japan Scientific Societies Press [Gakkai Shuppan Center], 1st Edition, published on May 30, 1986, pp.77 to 100). In breeding of amino acid-producing bacteria, the characteristic such as auxotrophy, L-amino acid analogue resistance and metabolic control mutation may be imparted alone or in combination of two or more. The L-amino acid biosynthetic enzyme activity may be enhanced alone or in combination of two or more. Further, imparting of the characteristic such as auxotrophy, L-amino acid analogue resistance and metabolic control mutation may be combined with enhancement of the L-amino acid biosynthesis enzyme activity.

[0014] For example, L-lysine-producing bacteria are bred as mutants exhibiting auxotrophy for L-homoserine or L-threonine and L-methionine (Japanese Patent Publication. (Kokoku) Nos. 48-28078/1973 and 56-6499/1981), mutants exhibiting auxotrophy for inositol or acetic acid (Japanese Patent Application Laid-open (Kokai) Nos. 55-9784/1980 and 56-8692/1981), or mutants that are resistant to oxalysine, lysine hydroxamate, S-(2-aminoethyl)-cysteine,  $\gamma$ -methyllysine,  $\alpha$ -chlorocaprolactam, DL- $\alpha$ -amino- $\epsilon$ -caprolactam,  $\alpha$ -aminolauryllactam, aspartic acid analogue, sulfa drug, quinoid or N-lauroylleucine.

[0015] Further, L-glutamic acid-producing bacteria can be bred as mutants exhibiting auxotrophy for oleic acid or the like. L-Threonine-producing bacteria can be bred as mutants resistant to  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid. L-Homoserine-producing bacteria can be bred as mutants exhibiting auxotrophy for L-threonine or mutants resistant to L-phenylalanine analogues. L-Phenylalanine-producing bacteria can be bred as mutants exhibiting auxotrophy for L-tyrosine. L-Isoleucine-producing bacteria can be bred as mutants exhibiting auxotrophy for L-leucine. L-Proline-producing bacteria can be bred as mutants exhibiting auxotrophy for L-isoleucine.

[0016] Furthermore, as mentioned in the examples hereinafter, strains that produce one or more kinds of branched amino acids (L-valine, L-leucine and L-isoleucine) can be obtained as strains exhibiting auxotrophy for casamino acid.

[0017] In order to obtain mutants from *Methylophilus* bacteria, the inventors of the present invention first examined details of an optimal mutagenesis condition by using emergence frequency of streptomycin resistant strains as an index. As a result, the maximum emergence frequency of streptomycin resistant strains was obtained when the survival rate after mutagenesis was about 0.5%, and they succeeded in obtaining auxotrophic strains under this condition. They also succeeded in obtaining auxotrophic strains, which had been considered difficult, by largely scaling up the screening of mutants compared with that previously conducted for *E. coli* and so forth.

[0018] As described above, since it has been revealed that mutants can be obtained by mutagenizing *Methylophilus* bacteria under a suitable condition, it has become possible to readily obtain desired mutants by suitably setting such a condition that the survival rate after the mutagenesis should become about 0.5%, depending on the mutagenesis method.

[0019] Mutagenesis methods for obtaining mutants from *Methylophilus* bacteria include UV irradiation and treatments with mutagenesis agents used for usual mutagenesis treatments such as *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (NTG) and nitrous acid. *Methylophilus* bacteria having L-amino acid-producing ability can also be obtained by selecting naturally occurring mutants of *Methylophilus* bacteria.

[0020] L-Amino acid analogue-resistant mutants can be obtained by, for example, inoculating mutagenized *Methylophilus* bacteria to an agar medium containing an L-amino acid analogue at a variety of concentrations and selecting strains that form colonies.

[0021] Auxotrophic mutants can be obtained by allowing *Methylophilus* bacteria to form colonies on an agar medium containing a target nutrient (for example, L-amino acid), replicating the colonies to an agar medium not containing said nutrient, and selecting strains that cannot grow on the agar medium not containing the nutrient.

[0022] Methods for imparting or enhancing L-amino acid-producing ability by enhancing L-amino acid biosynthetic enzyme activity will be exemplified below.

#### [L-Lysine]

[0023] L-Lysine-producing ability can be imparted by, for example, enhancing dihydronicotinate synthase activity and/or aspartokinase activity.

[0024] The dihydronicotinate synthase activity and/or the aspartokinase activity in *Methylophilus* bacteria can be enhanced by ligating a gene fragment coding for dihydronicotinate synthase and/or a gene fragment coding for aspartokinase with a vector that functions in *Methylophilus* bacteria, preferably a multiple copy type vector, to create a recombinant DNA, and introducing them into a *Methylophilus* bacterium host to transform the host. As a result of the

increase in the copy numbers of the gene coding for dihydrodipicolinate synthase and/or the gene coding for aspartokinase in cells of the transformant strain, the activity or activities thereof is/are enhanced. Hereafter, dihydrodipicolinate synthase, aspartokinase and aspartokinase III are also referred with abbreviations of DDPS, AK and AKIII, respectively.

5 [0025] As a microorganism providing a gene that codes for DDPS and a gene that codes for AK, any microorganisms can be used so long as they have genes enabling expression of DDPS activity and AK activity in microorganisms belonging to the genus *Methylophilus*. Such microorganisms may be wild strains or mutant strains derived therefrom.

10 Specifically, examples of such microorganisms include *E. coli* (*Escherichia coli*) K-12 strain, *Methylophilus methylo-trophus* AS1 strain (NCIMB10515) and so forth. Since nucleotide sequences of a gene coding for DDPS (*dapA*, Richardaud, F. et al., J. Bacteriol., 297, (1986)) and a gene coding for AKIII (*lysC*, Cassan, M., Parsot, C., Cohen, G.N. and Patte, J.C., J. Biol. Chem., 261, 1052 (1986)) derived from *Escherichia* bacteria have been both revealed, these genes can be obtained by PCR using primers synthesized based on the nucleotide sequences of these genes and chromosome DNA of microorganism such as *E. coli* K-12 or the like as a template. As specific examples, *dapA* and *lysC* derived from *E. coli* will be explained below. However, genes used for the present invention are not limited to them.

15 [0026] It is preferred that DDPS and AK used for the present invention do not suffer feedback inhibition by L-lysine. It has been known that wild-type DDPS derived from *E. coli* suffers feedback inhibition by L-lysine, and that wild-type AKIII derived from *E. coli* suffers suppression and feedback inhibition by L-lysine. Therefore, *dapA* and *lysC* to be introduced into *Methylophilus* bacteria preferably code for DDPS and AKIII having a mutation that desensitizes the feedback inhibition by L-lysine. Hereafter, DDPS having a mutation that desensitizes the feedback inhibition by L-lysine is also referred to as "mutant DDPS", and DNA coding for the mutant DDPS is also referred to as "mutant *dapA*". AKIII derived from *E. coli* having a mutation that desensitizes the feedback inhibition by L-lysine is also referred to as "mutant AKIII", and DNA coding for the mutant AKIII is also referred to as "mutant *lysC*".

20 [0027] According to the present invention, DDPS and AK are not necessarily required to be a mutant. It has been known that, for example, DDPS derived from *Corynebacterium* bacteria originally does not suffer feedback inhibition by L-lysine.

25 [0028] A nucleotide sequence of wild-type *dapA* derived from *E. coli* is exemplified by SEQ ID NO: 1. The amino acid sequence of wild-type DDPS coded by said nucleotide sequence is exemplified by SEQ ID NO: 2. A nucleotide sequence of wild-type *lysC* derived from *E. coli* is exemplified by SEQ ID NO: 3. The amino acid sequence of wild-type ATIII coded by said nucleotide sequence is exemplified by SEQ ID NO: 4.

30 [0029] The DNA coding for mutant DDPS that does not suffer feedback inhibition by L-lysine includes a DNA coding for DDPS having the amino acid sequence described in SEQ ID NO: 2 wherein the 118-histidine residue is replaced with a tyrosine residue. The DNA coding for mutant AKIII that does not suffer feedback inhibition by L-lysine includes a DNA coding for AKIII having an amino sequence described in SEQ ID NO: 4 wherein the 352-threonine residue is replaced with an isoleucine residue.

35 [0030] The plasmid used for gene cloning may be any plasmid so long as it can replicate in microorganisms such as *Escherichia* bacteria or the like, and specifically include pBR322, pTWV228, pMW119, pUC19 and so forth.

[0031] The vector that functions in *Methylophilus* bacteria is, for example, a plasmid that can autonomously replicate in *Methylophilus* bacteria. Specifically, there can be mentioned RSF1010, which is a broad host spectrum vector, and derivatives thereof, for example, pAYC32 (Chistorerdov, A.Y., Tsygankov, Y.D. Plasmid, 16, 161-167, (1986)), pMFY42 (Gene, 44, 53, (1990)), pRP301, pTB70 (Nature, 287, 396, (1980)) and so forth.

40 [0032] In order to prepare a recombinant DNA by ligating *dapA* and *lysC* to a vector that functions in *Methylophilus* bacteria, the vector is digested with a restriction enzyme that corresponds to the terminus of DNA fragment containing *dapA* and *lysC*. Ligation is usually performed by using ligase such as T4 DNA ligase. *dapA* and *lysC* may be individually incorporated into separate vectors or into a single vector.

45 [0033] As a plasmid containing a mutant *dapA* coding for mutant DDPS and a mutant *lysC* coding for mutant AKIII, a broad host spectrum plasmid RSFD80 has been known (WO95/16042). *E. coli* JM109 strain transformed with this plasmid was designated as AJ12396, and deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on October 28, 1993 and received an accession number of FERM P-13936, and it was transferred to an international deposition under the provisions of the Budapest Treaty on November 1, 1994, and received an accession number of FERM BP-4859. RSFD80 can be obtained from the AJ12396 strain in a known manner.

50 [0034] The mutant *dapA* contained in RSFD80 has a nucleotide sequence of wild-type *dapA* of SEQ ID NO: 1 including replacement of C at the nucleotide number 597 with T. The mutant DDPS encoded thereby has an amino acid sequence of SEQ ID NO: 2 including replacement of the 118-histidine residue with a tyrosine residue. The mutant *lysC* contained in RSFD80 has a nucleotide sequence of wild-type *lysC* of SEQ ID NO: 3 including replacement of C at the nucleotide number 1638 with T. The mutant AKIII encoded thereby has an amino acid sequence of SEQ ID NO: 4 including replacement of the 352-threonine residue with an isoleucine residue.

[0035] In order to introduce a recombinant DNA prepared as described above into *Methylophilus* bacteria, any method can be used so long as it provides sufficient transformation efficiency. For example, electroporation can be used (Canadian Journal of Microbiology, 43, 197 (1997)).

[0036] The DDPS activity and/or the AK activity can also be enhanced by the presence of multiple copies of *dapA* and/or *lysC* on chromosome DNA of *Methylophilus* bacteria. In order to introduce multiple copies of *dapA* and/or *lysC* into chromosome DNA of *Methylophilus* bacteria, homologous recombination is performed by using, as a target, a sequence that is present on chromosome DNA of *Methylophilus* bacteria in a multiple copy number. As the sequence present on chromosome DNA in the multiple copy number, a repetitive DNA, inverted repeats present at the end of a transposable element, or the like can be used. Alternatively, as disclosed in Japanese Patent Application Laid-open (Kokai) No. 2-109985/1990, multiple copies of *dapA* and/or *lysC* can be introduced into chromosome DNA by mounting them on a transposon to transfer them. In both of the methods, as a result of increased copy number of *dapA* and/or *lysC* in transformed strains, the DDPS activity and the AK activity should be amplified.

[0037] Besides the above gene amplification, the DDPS activity and/or the AK activity can be amplified by replacing an expression control sequence such as promoters of *dapA* and/or *lysC* with stronger ones (Japanese Patent Application Laid-open (Kokai) No. 1-215280/1989). As such strong promoters, there have been known, for example, *lac* promoter, *trp* promoter, *trc* promoter, *tac* promoter, *P<sub>R</sub>* promoter and *P<sub>L</sub>* promoter of lambda phage, tet promoter, *amyE* promoter, *spac* promoter and so forth. Substitution of these promoters enhances expression of *dapA* and/or *lysC*, and thus the DDPS activity and the AK activity are amplified. Enhancement of expression control sequences can be combined with increase of the copy numbers of *dapA* and/or *lysC*.

[0038] In order to prepare a recombinant DNA by ligating a gene fragment and a vector, the vector is digested with a restriction enzyme corresponding to the terminus of the gene fragment. Ligation is usually performed by ligase such as T4 DNA ligase. As methods for digestion, ligation and others of DNA, preparation of chromosome DNA, PCR, preparation of plasmid DNA, transformation, design of oligonucleotides used as primers and so forth, usual methods well known to those skilled in the art can be used. Such methods are described in Sambrook, J., Fritsch, E. F., and Maniatis, T., "Molecular Cloning: A Laboratory Manual, 2nd Edition", Cold Spring Harbor Laboratory Press, (1989) and so forth.

[0039] In addition to the enhancement of the DDPS activity and/or the AK activity, activity of another enzyme involved in the L-lysine biosynthesis may also be enhanced. Such enzymes include diaminopimelate pathway enzymes such as dihydrodipicolinate reductase, diaminopimelate decarboxylase, diaminopimelate dehydrogenase (WO96/40934 for all of the foregoing enzymes), phosphoenolpyruvate carboxylase (Japanese Patent Application Laid-open (Kokai) No. 60-87788/1985), aspartate aminotransferase (Japanese Patent Publication (Kokoku) No. 6-102028/1994), diaminopimelate epimerase, aspartic acid semialdehyde dehydrogenase and so forth, or amino adipate pathway enzymes such as homoaconitate hydratase and so forth. Preferably, activity of at least one enzyme of aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate reductase and diaminopimelate decarboxylase is enhanced.

[0040] Aspartokinase, aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate synthase, dihydrodipicolinate reductase and diaminopimelate decarboxylase derived from *Methylophilus methylotrophicus* will be described later.

[0041] Further, the microorganisms of the present invention may be decreased in activity of an enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine, or may be deficient in such an enzyme. The enzyme that catalyzes the reaction for generating the compound other than L-lysine by branching off from the biosynthetic pathway L-lysine include homoserine dehydrogenase (see WO95/23864).

[0042] The aforementioned techniques for enhancing activity of an enzyme involved in the L-lysine biosynthesis can be similarly used for other amino acids mentioned below.

#### 45 [L-Glutamic acid]

[0043] L-Glutamic acid-producing ability can be imparted to *Methylophilus* bacteria by, for example, introducing a DNA that codes for any one of enzymes including glutamate dehydrogenase (Japanese Patent Application Laid-open (Kokai) 61-268185/1986), glutamine synthetase, glutamate synthase, isocitrate dehydrogenase (Japanese Patent Application Laid-open (Kokai) Nos. 62-166890/1987 and 63-214189/1988), aconitate hydratase (Japanese Patent Application Laid-open (Kokai) No. 62-294086/1987), citrate synthase (Japanese Patent Application Laid-open (Kokai) Nos. 62-201585/1987 and 63-119688/1988), phosphoenolpyruvate carboxylase (Japanese Patent Application Laid-open (Kokai) Nos. 60-87788/1985 and 62-55089/1987), pyruvate dehydrogenase, pyruvate kinase, phosphoenolpyruvate synthase, enolase, phosphoglyceromutase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, triose phosphate isomerase, fructose bisphosphate aldolase, phosphofructokinase (Japanese Patent Application Laid-open (Kokai) No. 63-102692/1988), glucose phosphate isomerase, glutamine-oxoglutarate aminotransferase (WO99/07853) and so forth.

[0044] Further, the microorganisms of the present invention may be decreased in activity of an enzyme that catalyzes

EP 1 188 822 A1

a reaction for generating a compound other than L-glutamic acid by branching off from the biosynthetic pathway of L-glutamic acid, or may be deficient in such an enzyme. The enzyme that catalyzes the reaction for generating the compound other than L-glutamic acid by branching off from the biosynthetic pathway L-glutamic acid include  $\alpha$ -ketoglutarate dehydrogenase ( $\alpha$ KGDH), isocitrate lyase, phosphate acetyltransferase, acetate kinase, acetohydroxy acid synthase, acetolactate synthase, formate acetyltransferase, lactate dehydrogenase, glutamate decarboxylase, 1-pyrrolidine dehydrogenase and so forth.

[L-Threonine]

[0045] L-Threonine-producing ability can be imparted or enhanced by, for example, enhancing activities of aspartokinase, homoserine dehydrogenase, homoserine kinase and threonine synthase. The activities of these enzymes can be enhanced by, for example, transforming *Methylophilus* bacteria using a recombinant plasmid containing a threonine operon (Japanese Patent Application Laid-open (Kokai) Nos. 55-131397/1980, 59-31691/1984 and 56-15696/1981 and Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991).

[0046] The production ability can also be imparted or enhanced by amplifying or introducing a threonine operon having a gene coding for aspartokinase of which feedback inhibition by L-threonine is desensitized (Japanese Patent Publication (Kokoku) No. 1-29559/1989), a gene coding for homoserine dehydrogenase (Japanese Patent Application Laid-open (Kokai) No. 60-012995/1985) or a gene coding for homoserine kinase and homoserine dehydrogenase (Japanese Patent Application Laid-open (Kokai) No. 61-195695/1986).

[0047] Further, L-threonine-producing ability can be improved by introducing a DNA coding for a mutant phosphoenolpyruvate carboxylase having a mutation for desensitizing feedback inhibition by aspartic acid.

[L-Valine]

[0048] L-Valine-producing ability can be imparted by, for example, introducing into *Methylophilus* bacteria an L-valine biosynthesis gene whose control mechanism has been substantially desensitized. There may also be introduced a mutation that substantially desensitizes a control mechanism of an L-valine biosynthesis gene carried by a microorganism belonging to the genus *Methylophilus*.

[0049] Examples of the L-valine biosynthesis gene include, for example, the *ilvGMDA* operon of *E. coli*. Threonine deaminase encoded by an *ilvA* gene catalyzes the deamination reaction converting L-threonine into 2-ketobutyric acid, which is the rate-determining step of L-isoleucine biosynthesis. Therefore, in order to attain efficient progression of the L-valine synthesis reactions, it is preferable to use an operon that does not express threonine deaminase activity. Examples of the *ilvGMDA* operon that does not express such threonine deaminase activity include an *ilvGMDA* operon wherein a mutation for eliminating threonine deaminase activity is introduced into *ilvA*, or *ilvA* is disrupted, and an *ilvGMED* operon wherein *ilvA* is deleted.

[0050] Since the *ilvGMDA* operon suffers expression control of operon (attenuation) by L-valine and/or L-isoleucine and/or L-leucine, the region required for the attenuation is preferably removed or mutated to desensitize the suppression of expression by L-valine.

[0051] An *ilvGMDA* operon which does not express threonine deaminase activity and in which attenuation is desensitized as described above can be obtained by subjecting a wild-type *ilvGMDA* operon to a mutagenesis treatment or modifying it by means of gene recombination techniques (see WO96/06926).

[L-Leucine]

[0052] L-Leucine-producing ability is imparted or enhanced by, for example, introducing into a microorganism belonging to the genus *Methylophilus* an L-leucine biosynthesis gene whose control mechanism has been substantially desensitized, in addition to the above characteristics required for the production of L-valine. It is also possible to introduce such a mutation that the control mechanism of an L-leucine biosynthesis gene in a microorganism belonging to the genus *Methylophilus* should be substantially eliminated. Examples of such a gene include, for example, an *leuA* gene which provides an enzyme in which inhibition by L-leucine is substantially eliminated.

[L-Isoleucine]

[0053] L-Isoleucine-producing ability can be imparted by, for example, introducing a *thrABC* operon containing a *thrA* gene coding for aspartokinase I/homoserine dehydrogenase I derived from *E. coli* wherein inhibition by L-threonine has been substantially desensitized and an *ilvGMDA* operon which contains an *ilvA* gene coding for threonine deaminase wherein inhibition by L-isoleucine is substantially desensitized and whose region required for attenuation is removed (Japanese Patent Application Laid-open (Kokai) No. 8-47397/1996).

[Other amino acids]

- [0054] Biosyntheses of L-tryptophan, L-phenylalanine, L-tyrosine, L-threonine and L-isoleucine can be enhanced by increasing phosphoenolpyruvate-producing ability of *Methylophilus* bacteria (WO97/08333).
- [0055] The production abilities for L-phenylalanine and L-tyrosine are improved by amplifying or introducing a desensitized chorismate mutase-prephenate dehydratase (CM-PDT) gene (Japanese Patent Application Laid-open (Kokai) Nos. 5-236947/1993 and 62-130693/1987) and a desensitized 3-deoxy-D-arabinoheptulonate-7-phosphate synthase (DS) gene (Japanese Patent Application Laid-open (Kokai) Nos. 5-236947/1993 and 61-124375/1986).
- [0056] The producing ability of L-tryptophan is improved by amplifying or introducing a tryptophan operon containing a gene coding for desensitized anthranilate synthase (Japanese Patent Application Laid-open (Kokai) Nos. 57-71397/1982, 62-244382/1987 and US Patent No. 4,371,614).
- [0057] In the present specification, the expression that enzyme "activity is enhanced" usually refers to that the intracellular activity of the enzyme is higher than that of a wild type strain, and when a strain in which the activity of the enzyme is enhanced is obtained by modification using gene recombinant techniques or the like, the intracellular activity of the enzyme is higher than that of the strain before the modification. The expression that enzyme "activity is decreased" usually refers to that the intracellular activity of the enzyme is lower than that of a wild type strain, and when a strain in which the activity of the enzyme is decreased is obtained by modification using gene recombinant techniques or the like, the intracellular activity of the enzyme is lower than that of the strain before the modification.
- [0058] L-Amino acids can be produced by culturing *Methylophilus* bacteria having L-amino acid-producing ability obtained as described above in a medium to produce and accumulate L-amino acids in the culture, and collecting the L-amino acids from the culture.
- [0059] Bacterial cells of *Methylophilus* bacteria with an increased L-amino acid content compared with wild strains of *Methylophilus* bacteria can be produced by culturing *Methylophilus* bacteria having L-amino acid-producing ability in a medium to produce and accumulate L-amino acids in bacterial cells of the bacteria.
- [0060] Microorganisms used for the present invention can be cultured by methods usually used for culturing microorganisms having methanol-assimilating property. The medium used for the present invention may be a natural or synthetic medium so long as it contains a carbon source, a nitrogen source, inorganic ions and other trace amount organic constituents as required.
- [0061] By using methanol as a main carbon source, L-amino acids can be prepared at a low cost. When methanol is used as a main carbon source, it is usually added to a medium in an amount of 0.001 to 30%. As the nitrogen source, ammonium sulfate or the like is used by adding it to the medium. Other than these, there are usually added small amounts of the trace amount constituents such as potassium phosphate, sodium phosphate, magnesium sulfate, ferrous sulfate and manganese sulfate.
- [0062] The culture is usually performed under an aerobic condition obtained by, for example, shaking or stirring for aeration, at pH 5 to 9 and a temperature of 20 to 45°C, and it is usually completed within 24 to 120 hours.
- [0063] Collection of L-amino acids from culture can be usually attained by a combination of known methods such as those using ion exchange resin, precipitation and others.
- [0064] Further, *Methylophilus* bacterium cells can be separated from the medium by usual methods for separating microbial cells.

40 <2> Gene of the present invention

- [0065] The DNA of the present invention is a gene which codes for one of the enzymes, aspartokinase (henceforth also abbreviated as "AK"), aspartic acid semialdehyde dehydrogenase (henceforth also abbreviated as "ASD"), dihydronicotinate synthase (henceforth also abbreviated as "DDPS"), dihydronicotinate reductase (henceforth also abbreviated as "DDPR"), and diaminopimelate decarboxylase (henceforth also abbreviated as "DPDC") derived from *Methylophilus methylotrophicus*.
- [0066] The DNA of the present invention can be obtained by, for example, transforming a mutant strain of a microorganism deficient in AK, ASD, DDPS, DDPR or DPDC using a gene library of *Methylophilus methylotrophicus*, and selecting a clone in which auxotrophy is recovered.
- [0067] A gene library of *Methylophilus methylotrophicus* can be produced as follows, for example. First, total chromosome DNA is prepared from a *Methylophilus methylotrophicus* wild strain, for example, the *Methylophilus methylotrophicus* AS1 strain (NCIMB10515), by the method of Saito et al. (Saito, H. and Miura, K., Biochem. Biophys. Acta 72, 619-629, (1963)) or the like, and partially digested with a suitable restriction enzyme, for example, *Sau3A*I or *Apa*I, to obtain a mixture of various fragments. By controlling the degree of the digestion through adjustment of digestion reaction time and so forth, a wide range of restriction enzymes can be used.
- [0068] Subsequently, the digested chromosome DNA fragments are ligated to vector DNA autonomously replicable in *Escherichia coli* cells to produce recombinant DNA. Specifically, a restriction enzyme producing the same terminal

nucleotide sequence as that produced by the restriction enzyme used for the digestion of chromosome DNA is allowed to act on the vector DNA to fully digest and cleave the vector. Then, the mixture of chromosome DNA fragments and the digested and cleaved vector DNA are mixed, and a ligase, preferably T4 DNA ligase, is allowed to act on the mixture to obtain recombinant DNA.

5 [0069] A gene library solution can be obtained by transforming *Escherichia coli*, for example, the *Escherichia coli* JM109 strain or the like, using the obtained recombinant DNA, and preparing recombinant DNA from the culture broth of the transformant. This transformation can be performed by the method of D.M. Morrison (Methods in Enzymology 68, 326 (1979)), the method of treating recipient cells with calcium chloride so as to increase the permeability of DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)) and so forth. In the examples mentioned hereinafter, electroporation was used.

10 [0070] As examples of the aforementioned vector, there can be mentioned pUC19, pUC18, pUC118, pUC119, pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219, pMW218, pSTV28, pSTV29 and so forth. Phage vectors can also be used. Since pUC118 and pUC119 contain an ampicillin resistance gene, and pSTV28 and pSTV29 contain a chloramphenicol resistance gene, for example, only transformants which harbor a vector or a recombinant DNA can be grown by using a medium containing ampicillin or chloramphenicol.

15 [0071] As the method for culturing the transformants and collecting recombinant DNA from bacterial cells, the alkali SDS method and the like can be mentioned.

20 [0072] A mutant microbial strain deficient in AK, ASD, DDPS, DDPR or DPDC is transformed by using the gene library solution of *Methylophilus methylotrophicus* obtained as described above, and clones whose auxotrophy is recovered are selected.

25 [0073] Examples of a mutant microbial strain deficient in AK include *E. coli* GT3 deficient in three kinds of genes coding for AK (*thrA*, *metLM*, *lysC*). Examples of a mutant microbial strain deficient in ASD include *E. coli* Hfr3000 U482 (CGSC 5081 strain). Examples of a mutant microbial strain deficient in DDPS include *E. coli* AT997 (CGSC 4547 strain). Examples of a mutant microbial strain deficient in DDPR include *E. coli* AT999 (CGSC 4549 strain). Examples of a mutant microbial strain deficient in DPDC include *E. coli* AT2453 (CGSC 4505 strain). These mutant strains can be obtained from *E. coli* Genetic Stock Center (the Yale University, Department of Biology, Osborn Memorial Labs., P.O. Box 6666, New Haven 06511-7444, Connecticut, U.S.).

30 [0074] Although all of the aforementioned mutant strains cannot grow in M9 minimal medium, transformant strains which contain a gene coding for AK, ASD, DDPS, DDPR or DPDC can grow in M9 minimal medium because these genes function in the transformants. Therefore, by selecting transformant strains that can grow in the minimal medium and collecting recombinant DNA from the strains, DNA fragments containing a gene that codes for each enzyme can be obtained. *E. coli* AT999 (CGSC 4549 strain) shows extremely slow growth rate even in a complete medium such as L medium when diaminopimelic acid is not added to the medium. However, normal growth can be observed for its transformant strains which contain a gene coding for DDPR derived from *Methylophilus methylotrophicus*, because of the function of the gene. Therefore, a transformant strain that contains a gene coding for DDPR can also be obtained by selecting a transformant strain normally grown in L medium.

35 [0075] By extracting an insert DNA fragment from the obtained recombinant DNA and determining its nucleotide sequence, an amino acid sequence of each enzyme and nucleotide sequence of the gene coding for it can be determined.

40 [0076] The gene coding for AK of the present invention (henceforth also referred to "ask") codes for AK which has the amino acid sequence of SEQ ID NO: 6 shown in Sequence Listing. As a specific example of the *ask* gene, there can be mentioned a DNA having the nucleotide sequence which consists of nucleotides of SEQ ID NO: 5. The *ask* gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 6.

45 [0077] The gene which codes for ASD of the present invention (henceforth also referred to as "asd") codes for ASD which has the amino acid sequence of SEQ ID NO: 8 shown in Sequence Listing. As a specific example of the *asd* gene, a DNA which contains the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 98-1207 in SEQ ID NO: 7 can be mentioned. The *asd* gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 8.

50 [0078] The gene which codes for DDPS of the present invention (henceforth also referred to as "dapA") codes for DDPS which has the amino acid sequence of SEQ ID NO: 10 shown in Sequence Listing. As a specific example of the *dapA* gene, a DNA which has the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 1268-2155 in SEQ ID NO: 9 can be mentioned. The *dapA* gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 10.

55 [0079] The gene which codes for DDPR of the present invention (henceforth also referred to as "dapB") codes for

EP 1 188 822 A1

DDBR which has the amino acid sequence of SEQ ID NO: 12 shown in Sequence Listing. As a specific example of the *dapB* gene, a DNA which has the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 2080-2883 in SEQ ID NO: 11 can be mentioned. The *dapB* gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 12.

[0080] The gene which codes for DPDC of the present invention (henceforth also referred to as "*lysA*") codes for DPDC which has the amino acid sequence of SEQ ID NO: 14 shown in Sequence Listing. As a specific example of the *lysA* gene, a DNA which has the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 751-1995 in SEQ ID NO: 13 can be mentioned. The *lysA* gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 14.

[0081] The gene for each enzyme of the present invention may have an amino acid sequence corresponding to each amino acid sequence of SEQ ID NO: 6, 8, 10, 12 or 14 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and may code a protein having activity of AK, ASD, DDPS, DDPR or DPDC. The expression "one or several" used herein preferably means a number of 1 to 10, more preferably a number of 1 to 5, more preferably a number of 1 to 2.

[0082] The DNA which codes for the substantially same protein as AK, ASD, DDPS, DDPR or DPDC such as those mentioned above can be obtained by modifying each nucleotide sequence so that the amino acid sequence should contain substitution, deletion, insertion, addition or inversion of an amino acid residue or residues at a particular site by, for example, site-specific mutagenesis. Such a modified DNA as mentioned above may also be obtained by a conventional mutagenesis treatment. Examples of the mutagenesis treatment include in vitro treatment of DNA coding for AK, ASD, DDPS, DDPR or DPDC with hydroxylamine or the like, treatment of a microorganism such as *Escherichia* bacteria containing a gene coding for AK, ASD, DDPS, DDPR or DPDC by UV irradiation or with mutagenesis agents used for usual mutagenesis treatment such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) and nitrous acid.

[0083] The aforementioned substitution, deletion, insertion, addition or inversion of nucleotides includes naturally occurring mutations (mutant or variant) such as those observed depending difference between species or strains of microorganisms containing AK, ASD, DDPS, DDPR or DPDC and so forth.

[0084] The DNA which codes for substantially the same protein as AK, ASD, DDPS, DDPR or DPDC can be obtained by allowing expression of a DNA having such a mutation as mentioned above in a suitable cell, and examining AK, ASD, DDPS, DDPR or DPDC activity of the expression product. The DNA which codes for substantially the same protein as AK, ASD, DDPS, DDPR or DPDC can also be obtained by isolating, from DNAs coding for AK, ASD, DDPS, DDPR or DPDC which have mutations or cells containing each of them, a DNA hybridizable with a probe containing a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 510-1736 of SEQ ID NO: 5, a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 98-1207 of SEQ ID NO: 7, a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 1268-2155 of SEQ ID NO: 9, a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 2080-2883 of SEQ ID NO: 11, or a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 751-1995 of SEQ ID NO: 13, or a part of those nucleotide sequences under a stringent condition, and coding for a protein having AK, ASD, DDPS, DDPR or DPDC activity. In the present specification, to have a nucleotide sequence or a part thereof means to have the nucleotide sequence or the part thereof, or a nucleotide complementary thereto.

[0085] The term "stringent condition" used herein means a condition that allows formation of so-called specific hybrid and does not allow formation of non-specific hybrid. This condition may vary depending on the nucleotide sequence and length of the probe. However, it may be, for example, a condition that allows hybridization of highly homologous DNA such as DNA having homology of 40% or higher, but does not allow hybridization of DNA of lower homology than defined above, or a condition that allows hybridization under a washing condition of usual Southern hybridization, of a temperature of 60°C and salt concentrations corresponding to 1 x SSC and 0.1% SDS, preferably 0.1 x SSC and 0.1% SDS.

[0086] A partial sequence of each gene can also be used as the probe. Such a probe can be produced by PCR (polymerase chain reaction) using oligonucleotides produced based on a nucleotide sequence of each gene as primers and a DNA fragment containing each gene as a template. When a DNA fragment having a length of about 300 bp is used as the probe, washing condition for hybridization may be, for example, 50°C, 2 x SSC and 0.1% SDS.

[0087] Genes that hybridize under such a condition as mentioned above also include those having a stop codon occurring in its sequence and those encoding an enzyme no longer having its activity due to a mutation of active center. However, such genes can readily be eliminated by ligating the genes to a commercially available activity expression vector, and measuring AK, ASD, DDPS, DDPR or DPDC activity.

[0088] Since the nucleotide sequences of the genes that codes for AK, ASD, DDPS, DDPR and DPDC derived from *Methylophilus methylotrophus* were revealed by the present invention, DNA sequences which code for AK, ASD, DDPS, DDPR and DPDC can be obtained from a *Methylophilus methylotrophus* gene library by hybridization using oligonu-

EP 1 188 822 A1

cleotide probes produced based on the sequences. Moreover, DNA sequences which code for these enzymes can also be obtained by amplifying them from *Methylophilus methylotrophicus* chromosome DNA by PCR using oligonucleotide primers produced based on the aforementioned nucleotide sequences.

[0089] The aforementioned genes can suitably be utilized to enhance L-lysine-producing ability of *Methylophilus* bacteria.

5

**EXAMPLES**

[0090] The present invention will further specifically be explained with reference to the following examples hereafter.

10

[0091] The reagents used were obtained from Wako Pure Chemicals or Nakarai Tesque unless otherwise indicated. The compositions of the media used in each example are shown below. pH was adjusted with NaOH or HCl for all media.

15

| (L medium)                                 |        |
|--|--------|
| Bacto tryptone (DIFCO)                     | 10 g/L |
| Yeast extract (DIFCO)                      | 5 g/L  |
| NaCl                                       | 5 g/L  |
| [steam-sterilized at 120°C for 20 minutes] |        |

20

25

| (L agar medium)                            |        |
|--|--------|
| L medium                                   |        |
| Bacto agar (DIFCO)                         | 15 g/L |
| [steam-sterilized at 120°C for 20 minutes] |        |

30

35

| (SOC medium)            |        |
|-------------------------|--------|
| Bacto tryptone (DIFCO)  | 20 g/L |
| Yeast extract (DIFCO)   | 5 g/L  |
| 10 mM NaCl              |        |
| 2.5 mM KCl              |        |
| 10 mM MgSO <sub>4</sub> |        |
| 10 mM MgCl <sub>2</sub> |        |
| 20 mM Glucose           |        |

[The constituents except for magnesium solution and glucose were steam-sterilized (120°C, 20 minutes), then 2 M magnesium stock solution (1 M MgSO<sub>4</sub>, 1 M MgCl<sub>2</sub>) and 2 M glucose solution, which solutions had been passed through a 0.22-µm filter, were added thereto, and the mixture was passed through a 0.22-µm filter again.]

40

50

55

| (121M1 medium)                                  |          |
|---|----------|
| K <sub>2</sub> HPO <sub>4</sub>                 | 1.2 g/L  |
| KH <sub>2</sub> PO <sub>4</sub>                 | 0.62 g/L |
| NaCl  | 0.1 g/L  |
| (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> | 0.5 g/L  |
| MgSO <sub>4</sub> •7H <sub>2</sub> O            | 0.2 g/L  |
| CaCl <sub>2</sub> •6H <sub>2</sub> O            | 0.05 g/L |
| FeCl <sub>3</sub> •6H <sub>2</sub> O            | 1.0 mg/L |
| H <sub>3</sub> BO <sub>3</sub>                  | 10 µg/L  |
| CuSO <sub>4</sub> •5H <sub>2</sub> O            | 5 µg/L   |
| MnSO <sub>4</sub> •5H <sub>2</sub> O            | 10 µg/L  |
| ZnSO <sub>4</sub> •7H <sub>2</sub> O            | 70 µg/L  |
| NaMoO <sub>4</sub> •2H <sub>2</sub> O           | 10 µg/L  |

## EP 1 188 822 A1

(continued)

|                                      |        |
|--------------------------------------|--------|
| (121M1 medium)                       |        |
| CoCl <sub>2</sub> •6H <sub>2</sub> O | 5 µg/L |
| Methanol 1% (vol/vol), pH 7.0        |        |

[The constituents except for methanol were steam-sterilized at 121°C for 15 minutes. After the constituents sufficiently cooled, methanol was added.]

| (Composition of 121 production medium)       |          |  |
|--|----------|--|
| Methanol                                     | 2%       |  |
| Dipotassium phosphate                        | 0.12%    |  |
| Potassium phosphate                          | 0.062%   |  |
| Calcium chloride hexahydrate                 | 0.005%   |  |
| Magnesium sulfate heptahydrate               | 0.02%    |  |
| Sodium chloride                              | 0.01%    |  |
| Ferric chloride hexahydrate                  | 1.0 mg/L |  |
| Ammonium sulfate                             | 0.3%     |  |
| Cupric sulfate pentahydrate                  | 5 µg/L   |  |
| Manganous sulfate pentahydrate               | 10 µg/L  |  |
| Sodium molybdate dihydrate                   | 10 µg/L  |  |
| Boric acid                                   | 10 µg/L  |  |
| Zinc sulfate heptahydrate                    | 70 µg/L  |  |
| Cobaltous chloride hexahydrate               | 5 µg/L   |  |
| Calcium carbonate (Kanto Kagaku)<br>(pH 7.0) | 3%       |  |

|                     |        |
|---------------------|--------|
| (121M1 Agar medium) |        |
| 121M1 medium        |        |
| Bacto agar (DIFCO)  | 15 g/L |

[The constituents except for methanol were steam-sterilized at 121°C for 15 minutes. After the constituents sufficiently cooled, methanol was added.]

| (M9 minimal medium)                                  |             |  |
|--|-------------|--|
| Na <sub>2</sub> HPO <sub>4</sub> •12H <sub>2</sub> O | 16 g/L      |  |
| KH <sub>2</sub> PO <sub>4</sub>                      | 3 g/L       |  |
| NaCl   | 0.5 g/L     |  |
| NH <sub>4</sub> Cl                                   | 1 g/L       |  |
| MgSO <sub>4</sub> •7H <sub>2</sub> O                 | 246.48 mg/L |  |
| Glucose  | 2 g/L       |  |
| pH 7.0   |             |  |

[MgSO<sub>4</sub> and glucose were separately sterilized (120°C, 20 minutes) and added. A suitable amount of amino acids and vitamins were added as required.]

|                          |        |
|--------------------------|--------|
| (M9 minimal agar medium) |        |
| M9 minimal medium        |        |
| Bacto agar (DIFCO)       | 15 g/L |

## Example 1

## Creation of L-lysine-producing bacterium (1)

5 (1) Introduction of mutant *lysC* and mutant *dapA* into *Methylophilus* bacterium

[0092] A mutant *lysC* and a mutant *dapA* were introduced into a *Methylophilus* bacterium by using a known plasmid RSFD80 (see WO95/16042) containing them. RSFD80 is a plasmid pVIC40 (International Publication WO90/04636, Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) derived from a broad host spectrum vector plasmid pAYC32 (Chistorerdov, A.Y., Tsygankov, Y.D., Plasmid, 16, 161-167, (1986)), which is a derivative of RSF1010, in which a mutant *dapA* and a mutant *lysC* derived from *E. coli* are located in this order downstream of the promoter (*tetP*) of the tetracycline resistance gene of pVIC40 so that the transcription directions of the genes are ordinary with respect to *tetP*. The mutant *dapA* coded for a mutant DDPS in which the 118-histidine residue was replaced with a tyrosine residue. The mutant *lysC* coded for a mutant AKIII in which the 352-threonine residue was replaced with an isoleucine residue.

[0093] RSFD80 was constructed as follows. The mutant *dapA* on a plasmid pdapAS24 was ligated to pVIC40 at a position downstream of the promoter of the tetracycline resistance gene to obtain RSF24P as shown in Fig. 1. Then, the plasmid RSFD80 which had the mutant *dapA* and a mutant *lysC* was prepared from RSF24P and pLLC\*80 containing the mutant *lysC* as shown in Fig. 2. That is, while pVIC40 contains a threonine operon, this threonine operon is replaced with a DNA fragment containing the mutant *dapA* and a DNA fragment containing the mutant *lysC* in RSFD80.

[0094] The *E. coli* JM109 strain transformed with the RSFD80 plasmid was designated as AJ12396, and deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on October 28, 1993 and received an accession number of FERM P-13936, and it was transferred to an international deposition under the provisions of the Budapest Treaty on November 1, 1994, and received an accession number of FERM BP-4859.

[0095] The *E. coli* AJ1239 strain was cultured in 30 ml of LB medium containing 20 mg/L of streptomycin at 30°C for 12 hours, and the RSFD80 plasmid was purified from the obtained cells by using Wizard® Plus Midipreps DNA Purification System (sold by Promega).

[0096] The RSFD80 plasmid produced as described above was introduced into the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation (Canadian Journal of Microbiology, 43, 197 (1997)). As a control, a DNA region coding for the threonine operon was deleted from the pVIC40 plasmid used for producing the RSFD80 plasmid to produce a pRS plasmid comprising only the vector region (see Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991), and the pRS plasmid was introduced into the AS1 strain in the same manner as that used for RSFD80.

(2) AKIII Activity of *Methylophilus* bacterium containing mutant *lysC* and mutant *dapA* derived from *E. coli*

[0097] Cell-free extracts were prepared from the *Methylophilus methylotrophus* AS1 strain containing the RSFD80 plasmid (also referred to as "AS1/RSFD80" hereinafter) and the *Methylophilus methylotrophus* AS1 strain containing the pRS plasmid (also referred to as "AS1/pRS" hereinafter), and AK activity was measured. The cell-free extracts (crude enzyme solutions) were prepared as follows. The AS1/RSFD80 strain and AS1/pRS strain were each inoculated to 121 production medium of the above composition containing 20 mg/L of streptomycin, cultured at 37°C for 34 hours with shaking, and then calcium carbonate was removed and cells were harvested.

[0098] The bacterial cells obtained as described above were washed with 0.2% KCl under a condition of 0°C, suspended in 20 mM potassium phosphate buffer (pH 7) containing 10 mM MgSO<sub>4</sub>, 0.8 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and 0.03 M β-mercaptoethanol, and disrupted by sonication (0°C, 200 W, 10 minutes). The sonicated cell suspension was centrifuged at 33,000 rpm for 30 minutes under a condition of 0°C, and the supernatant was separated. To the supernatant, ammonium sulfate was added to 80% saturation, and the mixture was left at 0°C for 1 hour, and centrifuged. The pellet was dissolved in 20 mM potassium phosphate buffer (pH 7) containing 10 mM MgSO<sub>4</sub>, 0.8 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and 0.03 M β-mercaptoethanol.

[0099] The measurement of AK activity was performed in accordance with the method of Stadtman (Stadtman, E. R., Cohen, G.N., LeBras, G., and Robichon-Szulmajster, H., J. Biol. Chem., 236, 2033 (1961)). That is, a reaction solution of the following composition was incubated at 30°C for 45 minutes, and color development was caused by adding a FeCl<sub>3</sub> solution (2.8 N HCl: 0.4 ml, 12% TCA: 0.4 ml, 5% FeCl<sub>3</sub>•6H<sub>2</sub>O/0.1 N HCl: 0.7 ml). The reaction solution was centrifuged, and absorbance of the supernatant was measured at 540 nm. The activity was represented in terms of the amount of hydroxamic acid produced in 1 minute (1 U = 1 μmol/minute). The molar extinction coefficient was set to be 600. The reaction solution not containing potassium aspartate was used as a blank. When the enzymatic

EP 1 188 822 A1

activity was measured, L-lysine was added to the enzymatic reaction solution at various concentrations to examine degree of inhibition by L-lysine. The results are shown in Table 1.

| (Composition of reaction solution) |            |
|------------------------------------|------------|
| Reaction mixture *1                | 0.3 ml     |
| Hydroxylamine solution *2          | 0.2 ml     |
| 0.1 M Potassium aspartate (pH 7.0) | 0.2 ml     |
| Enzyme solution                    | 0.1 ml     |
| Water (balance)                    | Total 1 ml |

\*1: 1 M Tris-HCl (pH 8.1); 9 ml, 0.3 M MgSO<sub>4</sub>; 0.5 ml and 0.2 M ATP (pH 7.0); 5 ml

\*2: 8 M Hydroxylamine solution neutralized with KOH immediately before use

Table 1

| Strain     | AK activity (Specific activity*1) | Specific activity with 5 mM L-lysine | Desensitization degree of inhibition*2 (%) |
|------------|-----------------------------------|--------------------------------------|--|
| AS1/pRS    | 7.93                              | 9.07                                 | 114  |
| AS1/RSFD80 | 13.36                             | 15.33                                | 115  |

\*1: nmol/minute/mg protein

\*2: Activity retention ratio in the presence of 5 mM LERR-lysine

[0100] As shown in Table 1, AK activity was increased by about 1.7 times by the introduction of the RSFD80 plasmid. Further, it was confirmed that the inhibition by L-lysine was completely desensitized in AK derived from *E. coli* that was encoded by the RSFD80 plasmid. Moreover, it was found that AK that was originally retained by the AS1 strain was not inhibited by L-lysine alone. The inventors of the present invention have discovered that the AK derived from the AS1 strain was inhibited by 100% when 2 mM for each of L-lysine and L-threonine were present in the reaction solution (concerted inhibition).

(3) Production of L-lysine by *Methylophilus* bacterium containing mutant *lysC* and mutant *dapA* derived from *E. coli*

[0101] Then, the AS1/RSFD80 strain and the AS1/pRS strain were inoculated to 121 production medium containing 20 mg/L of streptomycin, and cultured at 37°C for 34 hours with shaking. After the culture was completed, the bacterial cells and calcium carbonate were removed by centrifugation, and L-lysine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 2.

Table 2

| Strain     | Production amount of L-lysine hydrochloride (g/L) |
|------------|---|
| AS1/pRS    | 0   |
| AS1/RSFD80 | 0.3   |

Example 2

Creation of L-lysine-producing bacterium (2)

(1) Introduction of *tac* promoter region into broad host spectrum vector

[0102] In order to produce a large amount of enzyme involved in the biosynthesis of L-lysine (Lys) in *Methylophilus methylotrophicus*, *tac* promoter was used for gene expression of the target enzyme. The promoter is frequently used in *E. coli*.

[0103] The *tac* promoter region was obtained by amplification through PCR using DNA of pKK233-3 (Pharmacia) as a template, DNA fragments having the nucleotide sequences of SEQ ID NOS: 15 and 16 as primers, and a heat-resistant DNA polymerase. The PCR was performed with a cycle of 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 60 seconds, which was repeated 30 times. Then, the amplified DNA fragment was collected and treated with

EP 1 188 822 A1

restriction enzymes *Eco*RI and *Pst*I. On the other hand, a broad host spectrum vector pRS (see Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) was also digested with the same restriction enzymes, and the aforementioned DNA fragment which contained the *tac* promoter region was introduced into the restriction enzyme digestion termini to construct pRS-tac.

5

(2) Preparation of *dapA* gene (dihydrodipicolinate synthase gene) expression plasmid pRS-dapA24 and *lysC* gene (aspartokinase gene) expression plasmid pRS-lysC80

[0104] A mutant gene (*dapA\*24*) coding for dihydrodipicolinate synthase whose feedback inhibition for the enzyme activity by Lys was partially desensitized was introduced into the plasmid pRS-tac which was prepared by the method described in the above (1).

[0105] First, the *dapA\*24* gene region was obtained by amplification through PCR using DNA of RSFD80 (see Example 1) as a template, and DNA fragments having the nucleotide sequences of SEQ ID NOS: 17 and 18 as primers. The PCR was performed with a cycle of 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 90 seconds, which was repeated 30 times. Then, the fragment was treated with restriction enzymes *Sse*8387I and *Xba*I to prepare a *dapA\*24* gene fragment having corresponding cleaved termini. On the other hand, pRS-tac was also treated with *Sse*8387I and partially digested with *Xba*I in the same manner as described above. To this digested plasmid, the aforementioned *dapA\*24* gene fragment was ligated by using T4 ligase to obtain pRS-dapA24.

[0106] Similarly, a gene (*lysC\*80*) coding for aspartokinase whose feedback inhibition for the enzyme activity by Lys was partially desensitized was obtained by PCR using DNA of RSFD80 as a template, and DNA fragments having the nucleotide sequences of SEQ ID NOS: 19 and 20 as primers. The PCR was performed with a cycle of 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 90 seconds, which was repeated 30 times. Then, the obtained DNA fragment was treated with restriction enzymes *Sse*8387I and *Sap*I. On the other hand, the vector pRS-tac was also treated with *Sse*8387I and *Sap*I. To this digested plasmid, the aforementioned *lysC\*80* gene fragment was ligated by using T4 ligase to obtain pRS-lysC80.

(3) Introduction of pRS-dapA24 or pRS-lysC80 into *Methylophilus methylotrophus* and evaluation of culture

[0107] Each of pRS-dapA24 and pRS-lysC80 obtained as described above was introduced into the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation to obtain AS1/pRS-dapA24 and AS1/pRS-lysC80, respectively. Each strain was inoculated to 121 production medium containing 20 mg/L of streptomycin, and cultured at 37°C for 48 hours with shaking. As a control strain, AS1 strain harboring pRS was also cultured in a similar manner. After the culture was completed, the cells and calcium carbonate were removed by centrifugation, and L-lysine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 3.

Table 3

| Strain         | Production amount of L-lysine hydrochloride (g/L) |
|----------------|---|
| AS1/pRS        | <0.01   |
| AS1/pRS-lysC80 | 0.06  |
| AS1/pRS-dapA24 | 0.13  |

45 Example 3

Creation of L-lysine-producing bacterium (3)

[0108] The *Methylophilus methylotrophus* AS1 strain (NCIMB10515) was inoculated to 121M1 medium and cultured at 37°C for 15 hours. The obtained bacterial cells were treated with NTG in a conventional manner (NTG concentration: 100 mg/L, 37°C, 5 minutes), and spread onto 121M1 agar medium containing 7 g/L of S-(2-aminoethyl)-cysteine (AEC) and 3 g/L of L-threonine. The cells were cultured at 37°C for 2 to 8 days, and the formed colonies were picked up to obtain AEC-resistant strains.

[0109] The aforementioned AEC-resistant strains were inoculated to 121 production medium, and cultured at 37°C for 38 hours under an aerobic condition. After the culture was completed, the cells and calcium carbonate were removed from the medium by centrifugation, and L-lysine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). A strain showing improved L-lysine-producing ability compared with the parent strain was selected, and designated as *Methylophilus meth-*

EP 1 188 822 A1

*ylotrophus* AR-166 strain. The L-lysine production amounts of the parent strain (AS1 strain) and the AR-166 strain are shown in Table 4.

Table 4

| Strain | Production amount of L-lysine hydrochloride (mg/L) |
|--------|--|
| AS1    | 5.8  |
| AR-166 | 80   |

[0110] The *Methylophilus methylotrophicus* AR-166 strain was given a private number of AJ13608, and was deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on June 10, 1999 and received an accession number of FERM P-17416, and it was transferred to an international deposition under the provisions of the Budapest Treaty on March 31, 2000, and received an accession number of FERM BP-7112.

Example 4

Creation of L-threonine-producing bacterium

(1) Introduction of threonine operon plasmid into *Methylophilus* bacterium

[0111] A plasmid pVIC40 (International Publication WO90/04636, Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) containing a threonine operon derived from *E. coli* was introduced into the *Methylophilus methylotrophicus* AS1 strain (NCIMB10515) by electroporation (Canadian Journal of Microbiology, 43, 197 (1997)) to obtain AS1/pVIC40 strain. As a control, pRS (Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) having only the vector region was obtained by deleting the DNA region coding for the threonine operon from the pVIC40 plasmid, and it was introduced into the AS1 strain in the same manner as used for pVIC40 to obtain AS1/pRS strain.

(2) Production of L-threonine by *Methylophilus* bacterium containing threonine operon derived from *E. coli*

[0112] Each of the AS1/pVIC40 and AS1/pRS strains was inoculated to 121 production medium containing 20 mg/L of streptomycin, 1 g/l of L-valine and 1 g/l of L-leucine, and cultured at 37°C for 50 hours with shaking. After the culture was completed, the cells and calcium carbonate were removed by centrifugation, and L-threonine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 5.

Table 5

| Strain     | Production amount of L-threonine (mg/L) |
|------------|---|
| AS1/pRS    | 15                                      |
| AS1/pVIC40 | 30                                      |

Example 5

Creation of branched chain amino acid-producing bacterium

[0113] The *Methylophilus methylotrophicus* AS1 strain (NCIMB10515) was inoculated to 121M1 medium and cultured at 37°C for 15 hours. The obtained bacterial cells were treated with NTG in a conventional manner (NTG concentration: 100 mg/L, 37°C, 5 minutes), and spread onto 121M1 agar medium containing 0.5% of casamino acid (DIFCO). The cells were cultured at 37°C for 2 to 8 days, and allowed to form colonies. The formed colonies were picked up, and inoculated to 121M1 agar medium and 121M1 agar medium containing 0.5% of casamino acid. Strains exhibiting better growth on the latter medium compared with on the former medium were selected as casamino acid auxotrophic strains. In this way, 9 leaky casamino acid auxotrophic strains were obtained from NTG-treated 500 strains. From these casamino acid auxotrophic strains, one strain that accumulated more L-valine, L-leucine and L-isoleucine in the medium compared with its parent strain was obtained. This strain was designated as *Methylophilus methylotrophicus* C138 strain.

[0114] The *Methylophilus methylotrophicus* C138 strain was given a private number of AJ13609, and was deposited

EP 1 188 822 A1

at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on June 10, 1999 and received an accession number of FERM P-17417, and it was transferred to an international deposition under the provisions of the Budapest Treaty on March 31, 2000, and received an accession number of FERM BP-7113.

[0115] The parent strain (AS1 strain) and the C138 strain were inoculated to 121 production medium, and cultured at 37°C for 34 hours under an aerobic condition. After the culture was completed, the cells and calcium carbonate were removed from the medium by centrifugation, and concentrations of L-valine, L-leucine and L-isoleucine in the culture supernatant were measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 6.

Table 6

| Strain | L-valine (mg/L) | L-leucine (mg/L) | L-isoleucine (mg/L) |
|--------|-----------------|------------------|---------------------|
| AS1    | 7.5             | 5.0              | 2.7                 |
| C138   | 330             | 166              | 249                 |

Example 6

Preparation of chromosome DNA library of *Methylophilus methylotrophus* AS1 strain

(1) Preparation of chromosome DNA of *Methylophilus methylotrophus* AS1 strain

[0116] One platinum loop of the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) was inoculated to 5 ml of 121M1 medium in a test tube, and cultured at 37°C overnight with shaking. The obtained culture broth was inoculated to 50 ml of 121M1 medium in a 500 ml-volume Sakaguchi flask in an amount of 1%, and cultured at 37°C overnight with shaking. Then, the cells were harvested by centrifugation, and suspended in 50 ml of TEN solution (solution containing 50 mM Tris-HCl (pH 8.0), 10 mM EDTA and 20 mM NaCl (pH 8.0)). The cells were collected by centrifugation, and suspended again in 5 ml of the TEN solution containing 5 mg/ml of lysozyme and 10 µg/ml of RNase A. The suspension was maintained at 37°C for 30 minutes, and then proteinase K and sodium laurylsulfate were added thereto to final concentrations of 10 µg/ml and 0.5% (wt/vol), respectively.

[0117] The suspension was maintained at 70°C for 2 hours, and then an equal amount of a saturated solution of phenol (phenol solution saturated with 10 mM Tris-HCl (pH 8.0)) was added and mixed. The suspension was centrifuged, and the supernatant was collected. An equal amount of phenol/chloroform solution (phenol:chloroform:isoamyl alcohol = 25:24:1) was added and mixed, and the mixture was centrifuged. The supernatant was collected, and an equal amount of chloroform solution (chloroform:isoamyl alcohol = 24:1) was added thereto to repeat the same extraction procedure. To the supernatant, a 1/10 volume of 3 M sodium acetate (pH 4.8) and 2.5-fold volume of ethanol were added to precipitate chromosome DNA. The precipitates were collected by centrifugation, washed with 70% ethanol, dried under reduced pressure, and dissolved in a suitable amount of TE solution (10 mM Tris-HCl, 1 mM EDTA (pH 8.0)).

(2) Preparation of gene library

[0118] A 50 µl portion of the chromosome DNA (1 µg/µl) obtained in the above (1), 20 µl of H buffer (500 mM Tris-HCl, 100 mM MgCl<sub>2</sub>, 10 mM dithiothreitol, 1000 mM NaCl (pH 7.5)) and 8 units of a restriction enzyme *Sau3AI* (Takara Shuzo) were allowed to react at 37°C for 10 minutes in a total volume of 200 µl, and then 200 µl of the phenol/chloroform solution was added and mixed to stop the reaction. The reaction mixture was centrifuged, and the upper layer was collected and separated on a 0.8% agarose gel. DNA corresponding to 2 to 5 kilobase pair (henceforth abbreviated as "kbp") was collected by using Concert™ Rapid Gel Extraction System (DNA collecting kit, GIBCO BRL Co.). In this way, 50 µl of a solution of DNA with fractionated size was obtained.

[0119] On the other hand, 2.5 µg of plasmid pUC118 (Takara Shuzo), 2 µl of K buffer (200 mM Tris-HCl, 100 mM MgCl<sub>2</sub>, 10 mM dithiothreitol, 1000 mM KCl (pH 8.5)) and 10 units of restriction enzyme *BamHI* (Takara Shuzo) were allowed to react at 37°C for 2 hours in a total volume of 20 µl, then 20 units of calf small intestine alkaline phosphatase (Takara Shuzo) was added and mixed, and the mixture was allowed to react for further 30 minutes. The reaction mixture was mixed with an equal amount of the phenol/chloroform solution, and the mixture was centrifuged. The supernatant was collected, and an equal amount of the chloroform solution was added thereto to repeat a similar extraction procedure. To the supernatant, a 1/10 volume of 3 M sodium acetate (pH 4.8) and 2.5-fold volume of ethanol were added to precipitate DNA. The DNA was collected by centrifugation, washed with 70% ethanol, dried under reduced pressure,

EP 1 188 822 A1

and dissolved in a suitable amount of TE solution.

[0120] A *Sau3AI* digestion product of the chromosome DNA prepared as described above and a *BamHI* digestion product of pUC118 were ligated by using a Ligation Kit ver. 2 (Takara Shuzo). To the reaction mixture, a 1/10 volume of 3 M sodium acetate (pH 4.8) and 2.5-fold volume of ethanol were added to precipitate DNA. The DNA was collected by centrifugation, washed with 70% ethanol, dried under reduced pressure, and dissolved in TE solution (Ligase solution A).

[0121] In the same manner as in the above procedure, fragments obtained by partial digestion of the chromosome DNA with a restriction enzyme *AluI* (Takara Shuzo) and a *SmaI* digestion product of plasmid pSTV29 (Takara Shuzo) were ligated (Ligase solution B).

[0122] One platinum loop of *E. coli* JM109 was inoculated to 5 ml of L medium in a test tube, and cultured at 37°C overnight with shaking. The obtained culture broth was inoculated to 50 ml of L medium in a 500 ml-volume Sakaguchi flask in an amount of 1%, cultured at 37°C until OD<sub>660</sub> of the culture became 0.5 to 0.6, and cooled on ice for 15 minutes. Then, the cells were harvested by centrifugation at 4°C. The cells were suspended in 50 ml of ice-cooled water and centrifuged to wash the cells. This operation was repeated once again, and the cells were suspended in 50 ml of ice-cooled 10% glycerol solution, and centrifuged to wash the cells. The cells were suspended in 10% glycerol solution of the same volume as the cells, and divided into 50 µl aliquots. To the cells in the 50 µl volume, 1 µl of Ligase solution A or Ligase solution B prepared above was added. Then, the mixture was put into a special cuvette (0.1 cm width, preliminarily ice-cooled) for an electroporation apparatus of BioRad.

[0123] The setting of the apparatus was 1.8 kV and 25 µF, and the setting of pulse controller was 200 ohms. The cuvette was mounted on the apparatus and pulses were applied thereto. Immediately after the application of pulse, 1 ml of ice-cooled SOC medium was added thereto, and the mixture was transferred into a sterilized test tube, and cultured at 37°C for 1 hour with shaking. Each cell culture broth was spread onto L agar medium containing an antibiotic (100 µg/ml of ampicillin when Ligase solution A was used, or 20 µg/ml of chloramphenicol when Ligase solution B was used), and incubated at 37°C overnight. The colonies emerged on each agar medium were scraped, inoculated to 50 ml of L medium containing respective antibiotic in a 500 ml-volume Sakaguchi flask, and cultured at 37°C for 2 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkali SDS method to form Gene library solution A and Gene library solution B, respectively.

Example 7

Cloning of lysine biosynthesis gene of *Methylophilus methylotrophicus* AS1 strain

(1) Cloning of gene coding for aspartokinase (AK)

[0124] *E. coli* GT3 deficient in the three genes coding for AK (*thrA*, *metLM* and *lysC*) was transformed with Gene library solution B by the same electroporation procedure as mentioned above. SOC medium containing 20 µg/ml of diaminopimelic acid was added to the transformation solution, and cultured at 37°C with shaking. Then, the culture broth was spread onto L medium containing 20 µg/ml of diaminopimelic acid and 20 µg/ml of chloramphenicol to obtain emerged colonies. This was replicated as a master plate to M9 agar medium containing 20 µg/ml of chloramphenicol, and the replicate was incubated at 37°C for 2 to 3 days. The host could not grow in M9 minimal medium that did not contain diaminopimelic acid since it did not have AK activity. In contrast, it was expected that the transformant strain that contained the gene coding for AK derived from *Methylophilus methylotrophicus* could grow in M9 minimal medium because of the function of the gene.

[0125] Two transformants out of about 3000 transformants formed colonies on M9 medium. Plasmids were extracted from the colonies emerged on M9 medium and analyzed. As a result, the presence of an inserted fragment on the plasmids was confirmed. The plasmids were designated as pMMASK-1 and pMMASK-2, respectively. By using these plasmids, *E. coli* GT3 was transformed again. The obtained transformants could grow on M9 minimal medium. Further, the transformant which contained each of these plasmids was cultured overnight in L medium containing 20 µg/ml of chloramphenicol, and the cells were collected by centrifugation of the culture broth. Cell-free extracts were prepared by sonicating the cells, and AK activity was measured according to the method of Miyajima et al. (Journal of Biochemistry (Tokyo), vol. 63, 139-148 (1968)) (Fig. 3: pMMASK-1, pMMASK-2). In addition, a GT3 strain harboring the vector pSTV29 was similarly cultured in L medium containing 20 µg/ml of diaminopimelic acid and 20 µg/ml of chloramphenicol, and AK activity was measured (Fig. 3: Vector). As a result, increase in AK activity was observed in two of the clones containing the inserted fragments compared with the transformant harboring only the vector. Therefore, it was confirmed that the gene that could be cloned on pSTV29 was a gene coding for AK derived from *Methylophilus methylotrophicus*. This gene was designated as *ask*.

[0126] The DNA nucleotide sequence of the *ask* gene was determined by the dideoxy method. It was found that pMMASK-1 and pMMASK-2 contained a common fragment. The nucleotide sequence of the DNA fragment containing

the *ask* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 5. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 5 and 6.

(2) Cloning of gene coding for aspartic acid semialdehyde dehydrogenase (ASD)

- [0127] *E. coli* Hfr3000 U482 (CGSC 5081 strain) deficient in the *asd* gene was transformed by electroporation using Gene library solution B in the same manner as described above. To the transformation solution, SOC medium containing 20 µg/ml of diaminopimelic acid was added and the mixture was cultured at 37°C with shaking. The cells were harvested by centrifugation. The cells were washed by suspending them in L medium and centrifuging the suspension. The same washing operation was repeated once again, and the cells were suspended in L medium. Then, the suspension was spread onto L agar medium containing 20 µg/ml of chloramphenicol, and incubated overnight at 37°C. The host showed extremely slow growth in L medium not containing diaminopimelic acid since it was deficient in the *asd* gene. In contrast, it was expected that normal growth would be observed for a transformant strain which contained the gene coding for ASD derived from *Methylophilus methylotrophus* even in L medium because of the function of the gene. Further, the host *E. coli* could not grow in M9 minimal medium, but a transformant strain that contained the gene coding for ASD derived from *Methylophilus methylotrophus* was expected to be able to grow in M9 minimal medium because of the function of the gene. Therefore, colonies of transformants that normally grew on L medium were picked up, streaked and cultured on M9 agar medium. As a result, growth was observed. Thus, it was confirmed that the gene coding for ASD functioned in these transformant strains as expected.
- [0128] Plasmids were extracted from the three transformant strains emerged on M9 medium, and the presence of an inserted fragment in the plasmids was confirmed. The plasmids were designated as pMMASD-1, pMMASD-2 and pMMASD-3, respectively. When the *E. coli* Hfr3000 U482 was transformed again by using these plasmids, each transformant grew in M9 minimal medium. Further, each transformant was cultured overnight in L medium containing 20 µg/ml of chloramphenicol, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a crude enzyme solution, and ASD activity was measured according to the method of Boy et al. (Journal of Bacteriology, vol. 112 (1), 84-92 (1972)) (Fig. 4: pMMASD-1, pMMASD-2, pMMASD-3). In addition, the host harboring the vector was similarly cultured in L medium containing 20 µg/ml of diaminopimelic acid and 20 µg/ml of chloramphenicol, and ASD activity was measured as a control experiment (Fig. 4: Vector). As a result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the ASD activity could be detected in three of the clones having an insert fragment. Therefore, it was confirmed that the obtained gene was a gene coding for ASD derived from *Methylophilus methylotrophus* (designated as *asd*).
- [0129] The DNA nucleotide sequence of the *asd* gene was determined by the dideoxy method. It was found that all of the three obtained clones contained a common fragment. The nucleotide sequence of the DNA fragment containing the *asd* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 7. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 7 and 8.

(3) Cloning of gene coding for dihydروpicolinate synthase (DDPS)

- [0130] *E. coli* AT997 (CGSC 4547 strain) deficient in the *dapA* gene was transformed by the same electroporation procedure using Gene library solution A. To the transformation solution, SOC medium containing 20 µg/ml of diaminopimelic acid was added, and the mixture was cultured at 37°C with shaking. Then, the culture broth was spread onto L medium containing 20 µg/ml of diaminopimelic acid and 100 µg/ml of ampicillin to obtain emerged colonies. This was replicated as a master plate to M9 minimal agar medium containing 100 µg/ml of ampicillin, and the replicate was incubated at 37°C for 2 to 3 days. The host could not grow in M9 minimal medium that did not contain diaminopimelic acid since it was deficient in *dapA* gene. In contrast, it was expected that a transformant strain that contained the gene coding for DDPS derived from *Methylophilus methylotrophus* could grow in M9 minimal medium because of the function of that gene.
- [0131] Plasmids were extracted from the colonies of two strains emerged on M9 medium, and analyzed. As a result, the presence of an inserted fragment in the plasmids was confirmed. The plasmids were designated as pMMDAPA-1 and pMMDAPA-2, respectively. When *E. coli* AT997 was transformed again by using these plasmids, each transformant was grown in M9 minimal medium. Further, each transformant containing each plasmid was cultured overnight in L medium containing 100 µg/ml of ampicillin, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a cell extract, and DDPS activity was measured according to the method of Yugari et al. (Journal of Biological Chemistry, vol. 240, and p. 4710 (1965)) (Fig. 5: pMMDAPA-1, pMMDAPA-2). In addition, the host harboring the vector was similarly cultured in L medium containing 20 µg/ml of diaminopimelic acid and 100 µg/ml of ampicillin, and DDPS activity was measured as a control experiment (Fig. 5: Vector). As a result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the DDPS activity could be detected in each of the transformants harboring the plasmids having the insert fragment. Therefore, it was confirmed that the

obtained gene was a gene coding for DDPS derived from *Methylophilus methylotrophus* (designated as *dapA*).

[0132] The DNA nucleotide sequence of the *dapA* gene was determined by the dideoxy method. It was found that two of the inserted fragments contained a common fragment. The nucleotide sequence of the DNA fragment containing the *dapA* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 9. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 9 and 10.

(4) Cloning of gene coding for dihydrodipicolinate reductase (DDPR)

[0133] *E. coli* AT999 (CGSC 4549 strain) deficient in the *dapB* gene was transformed by the same electroporation procedure as described above using Gene library solution A. To the transformation solution, SOC medium containing 20 µg/ml of diaminopimelic acid was added, and the mixture was cultured at 37°C with shaking. Then, the cells were harvested by centrifugation. The cells were washed by suspending them in L medium and centrifuging the suspension. The same washing operation was repeated once again, and the cells were suspended in L medium. Then, the suspension was spread onto L agar medium containing 100 µg/ml of ampicillin, and incubated overnight at 37°C. The host showed extremely slow growth in L medium not containing diaminopimelic acid since it was deficient in the *dapB* gene. In contrast, it was expected that normal growth could be observed for a transformant strain that contained the gene coding for DDPR derived from *Methylophilus methylotrophus* even in L medium because of the function of the gene. Further, the host *E. coli* could not grow in M9 minimal medium, but it was expected that a transformant strain which contained the gene coding for DDPR derived from *Methylophilus methylotrophus* could grow in M9 minimal medium because of the function of the gene.

[0134] Therefore, a colony of transformant that normally grew on L medium was streaked and cultured on M9 agar medium. Then, growth was also observed on M9 medium. Thus, it was confirmed that the gene coding for DDPR functioned in the transformant strain. A plasmid was extracted from the colony emerged on M9 medium, and the presence of an inserted fragment in the plasmid was confirmed. When *E. coli* AT999 was transformed again by using the plasmid (pMMDAPB), the transformant grew in M9 minimal medium. Further, the transformant containing the plasmid was cultured overnight in L medium, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a cell extract, and DDPR activity was measured according to the method of Tamir et al. (Journal of Biological Chemistry, vol. 249, p.3034 (1974)) (Fig. 6: pMMDAPB). In addition, the host harboring the vector was similarly cultured in L medium containing 20 µg/ml diaminopimelic acid and 100 µg/ml of ampicillin, and DDPR activity was measured as a control experiment (Fig. 6: Vector). As a result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the DDPR activity could be detected for the transformant harboring pMMDAPB. Therefore, it was confirmed that the obtained gene was a gene coding for DDPR derived from *Methylophilus methylotrophus* (designated as *dapB*).

[0135] The DNA nucleotide sequence of the *dapB* gene was determined by the dideoxy method. The nucleotide sequence of the DNA fragment containing the *dapB* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 11. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 11 and 12.

(5) Cloning of gene coding for diaminopimelate decarboxylase (DPDC)

[0136] *E. coli* AT2453 (CGSC 4505 strain) deficient in the *lysA* gene was transformed by the same electroporation procedure as described above using Gene library solution A. The transformation solution, SOC medium was added, and the mixture was cultured at 37°C with shaking. The cells were harvested by centrifugation. The cells were washed by suspending them in 5 ml of sterilized water and centrifuging the suspension. The same washing operation was repeated once again, and the cells were suspended in 500 µl of sterilized water. Then, the suspension was spread onto M9 minimal agar medium containing 20 µg/ml of chloramphenicol, and incubated at 37°C for 2 to 3 days. The host could not grow in M9 minimal medium not containing lysine since it was deficient in the *lysA* gene. In contrast, it was expected that a transformant strain that contained the gene coding for DPDC derived from *Methylophilus methylotrophus* could grow in M9 minimal medium because of the function of the gene.

[0137] Therefore, plasmids were extracted from the three transformant strains emerged on M9 medium, and analyzed. As a result, the presence of an inserted fragment in the plasmids was confirmed. The plasmids were designated as pMMLYSA-1, pMMLYSA-2 and pMMLYSA-3, respectively. When *E. coli* AT2453 was transformed again by using each of these plasmids, each transformant grew in M9 minimal medium. Further, each transformant containing each plasmid was cultured overnight in L medium containing 20 µg/ml of chloramphenicol, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a cell extract, and DPDC activity was measured according to the method of Cremer et al. (Journal of General Microbiology, vol. 134, 3221-3229 (1988)) (Fig. 7: pMMLYSA-1, pMMLYSA-2, pMMLYSA-3). In addition, the host harboring the vector was similarly cultured in L medium containing 20 µg/ml of chloramphenicol, and DPDC activity was measured as a control experiment (Fig. 7: Vector). As a

EP 1 188 822 A1

result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the DPDC activity could be detected in three of the clones having an insert fragment. Therefore, it was confirmed that the obtained gene was a gene coding for DPDC derived from *Methylophilus methylotrophicus* (designated as *lysA*).

5 [0138] The DNA nucleotide sequence of the *lysA* gene was determined by the dideoxy method. It was found that all of the three inserted fragments contained a common DNA fragment. The nucleotide sequence of the DNA fragment containing the *lysA* gene derived from *Methylophilus methylotrophicus* is shown in SEQ ID NO: 13. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 13 and 14.

10 Industrial Applicability

[0139] According to the present invention, there are provided a *Methylophilus* bacterium having L-amino acid-producing ability, a method for producing an L-amino acid using the *Methylophilus* bacterium, and *Methylophilus* bacterial cells with increased content of an L-amino acid. By the method of the present invention, it is enabled to produce an L-amino acid using methanol as a raw material. Moreover, novel L-lysine biosynthesis enzyme genes derived from *Methylophilus* bacteria are provided by the present invention.

20

25

30

35

40

45

50

55

## **SEQUENCE LISTING**

5 <110> Ajinomoto Co., Inc.

<120> L-AMINO ACID-PRODUCING BACTERIUM AND METHOD FOR PRODUCING L-AMINO ACID

<130> EPA-53711

15 <150> JP 11-103143

<151> 1999-04-09

<150> JP 11-169447

<151> 1999-06-16

<150> JP 11-368097

25 <151> 1999-12-24

<160> 20

**30** <170> Patent.In Ver. 2.0

<210> 1

<211> 1197

<212> DNA

<213> Escherichia coli

40

1000:

200

4-221- 603  
4-220- 603

888 (212)...(1141)

43 <100> 1

2020年

Met Phe Thr Gly Ser Ile Val

## EP 1 188 822 A1

|    | 1   | 5   |     |
|----|---|-----|-----|
| 5  | gct att gtt act ccg atg gat gaa aaa ggt aat gtc tgt cgg gct agc |     | 340 |
|    | Ala Ile Val Thr Pro Met Asp Glu Lys Gly Asn Val Cys Arg Ala Ser |     |     |
|    | 10  | 15  | 20  |
| 10 | ttg aaa aaa ctg att gat tat cat gtc gcc agc ggt act tcg gcg atc |     | 388 |
|    | Leu Lys Lys Leu Ile Asp Tyr His Val Ala Ser Gly Thr Ser Ala Ile |     |     |
|    | 25  | 30  | 35  |
| 15 | gtt tct gtt ggc acc act ggc gag tcc gct acc tta aat cat gac gaa |     | 436 |
|    | Val Ser Val Gly Thr Thr Gly Glu Ser Ala Thr Leu Asn His Asp Glu |     |     |
|    | 40  | 45  | 55  |
| 20 | cat gct gat gtg gtg atg atg acg ctg gat ctg gct gat ggg cgc att |     | 484 |
|    | His Ala Asp Val Val Met Met Thr Leu Asp Leu Ala Asp Gly Arg Ile |     |     |
|    | 60  | 65  | 70  |
| 25 | ccg gta att gcc ggg acc ggc gct aac gct act gct gaa gcc att agc |     | 532 |
|    | Pro Val Ile Ala Gly Thr Gly Ala Asn Ala Thr Ala Glu Ala Ile Ser |     |     |
|    | 75  | 80  | 85  |
| 30 | ctg acg cag cgc ttc aat gac agt ggt atc gtc ggc tgc ctg acg gta |     | 580 |
|    | Leu Thr Gln Arg Phe Asn Asp Ser Gly Ile Val Gly Cys Leu Thr Val |     |     |
|    | 90  | 95  | 100 |
| 35 | acc cct tac tac aat cgt ccg tcg caa gaa ggt ttg tat cag cat ttc |     | 628 |
|    | Thr Pro Tyr Tyr Asn Arg Pro Ser Gln Glu Gly Leu Tyr Gln His Phe |     |     |
|    | 105   | 110 | 115 |
| 40 | aaa gcc atc gct gag cat act gac ctg ccg caa att ctg tat aat gtg |     | 676 |
|    | Lys Ala Ile Ala Glu His Thr Asp Leu Pro Gln Ile Leu Tyr Asn Val |     |     |
|    | 120   | 125 | 130 |
| 45 | ccg tcc cgt act ggc tgc gat ctg ctc ccg gaa acg gtg ggc cgt ctg |     | 724 |
|    | Pro Ser Arg Thr Gly Cys Asp Leu Leu Pro Glu Thr Val Gly Arg Leu |     |     |
|    | 140   | 145 | 150 |
| 50 | gct aaa gta aaa aat att atc gga atc aaa gag gca aca ggg aac tta |     | 772 |
|    | Ala Lys Val Lys Asn Ile Ile Gly Ile Lys Glu Ala Thr Gly Asn Leu |     |     |
|    | 155   | 160 | 165 |
| 55 | acg cgt gta aac cag atc aaa gag ctg gtt tca gat gat ttt gtt ctg |     | 820 |
|    | Thr Arg Val Asn Gln Ile Lys Glu Leu Val Ser Asp Asp Phe Val Leu |     |     |
|    | 170   | 175 | 180 |
| 60 | ctg agc ggc gat gat gct agc gct ctg gac ttc atg caa ttg ggc ggt |     | 868 |
|    | Leu Ser Gly Asp Asp Ala Ser Ala Leu Asp Phe Met Gln Leu Gly Gly |     |     |
|    | 185   | 190 | 195 |
| 65 | cat ggg gtt att tcc gtt acg act aac gtc gca gct cgt gat atg gcc |     | 916 |

## EP 1 188 822 A1

His Gly Val Ile Ser Val Thr Thr Asn Val Ala Ala Arg Asp Met Ala  
 200 205 210 215  
 5 cag atg tgc aaa ctg gca gca gaa gaa cat ttt gcc gag gca cgc gtt 964  
 Gln Met Cys Lys Leu Ala Ala Glu Glu His Phe Ala Glu Ala Arg Val  
 220 225 230  
 10 att aat cag cgt ctg atg cca tta cac aac aaa cta ttt gtc gaa ccc 1012  
 Ile Asn Gln Arg Leu Met Pro Leu His Asn Lys Leu Phe Val Glu Pro  
 235 240 245  
 15 aat cca atc ccg gtg aaa tgg gca tgt aag gaa ctg ggt ctt gtg gcg 1060  
 Asn Pro Ile Pro Val Lys Trp Ala Cys Lys Glu Leu Gly Leu Val Ala  
 250 255 260  
 20 acc gat acg ctg cgc ctg cca atg aca cca atc acc gac agt ggt cgt 1108  
 Thr Asp Thr Leu Arg Leu Pro Met Thr Pro Ile Thr Asp Ser Gly Arg  
 265 270 275  
 25 gag acg gtc aga gca gca ctt aag cat gcc ggt ttg ctg taaaagtttag 1157  
 Glu Thr Val Arg Ala Ala Leu Lys His Ala Gly Leu Leu  
 280 285 290  
 29 ggagatttga tggcttactc tggcaaaag tcgcgcctgg 1197  
 30 <210> 2  
 <211> 292  
 <212> PRT  
 <213> Escherichia coli  
 35 <400> 2  
 Met Phe Thr Gly Ser Ile Val Ala Ile Val Thr Pro Met Asp Glu Lys  
 1 5 10 15  
 40 Gly Asn Val Cys Arg Ala Ser Leu Lys Lys Leu Ile Asp Tyr His Val  
 20 25 30  
 Ala Ser Gly Thr Ser Ala Ile Val Ser Val Gly Thr Thr Gly Glu Ser  
 45 35 40 45  
 Ala Thr Leu Asn His Asp Glu His Ala Asp Val Val Met Met Thr Leu  
 50 55 60  
 50 Asp Leu Ala Asp Gly Arg Ile Pro Val Ile Ala Gly Thr Gly Ala Asn  
 65 70 75 80  
 Ala Thr Ala Glu Ala Ile Ser Leu Thr Gln Arg Phe Asn Asp Ser Gly  
 85 90 95  
 55 Ile Val Gly Cys Leu Thr Val Thr Pro Tyr Tyr Asn Arg Pro Ser Gln

EP 1 188 822 A1

100                105                110  
Glu Gly Leu Tyr Gln His Phe Lys Ala Ile Ala Glu His Thr Asp Leu  
5                115                120                125  
Pro Gln Ile Leu Tyr Asn Val Pro Ser Arg Thr Gly Cys Asp Leu Leu  
10                130                135                140  
Pro Glu Thr Val Gly Arg Leu Ala Lys Val Lys Asn Ile Ile Gly Ile  
145                150                155                160  
Lys Glu Ala Thr Gly Asn Leu Thr Arg Val Asn Gln Ile Lys Glu Leu  
165                170                175  
15                Val Ser Asp Asp Phe Val Leu Leu Ser Gly Asp Asp Ala Ser Ala Leu  
180                185                190  
Asp Phe Met Gln Leu Gly Gly His Gly Val Ile Ser Val Thr Thr Asn  
20                195                200                205  
Val Ala Ala Arg Asp Met Ala Gln Met Cys Lys Leu Ala Ala Glu Glu  
210                215                220  
His Phe Ala Glu Ala Arg Val Ile Asn Gln Arg Leu Met Pro Leu His  
25                225                230                235                240  
Asn Lys Leu Phe Val Glu Pro Asn Pro Ile Pro Val Lys Trp Ala Cys  
245                250                255  
30                Lys Glu Leu Gly Leu Val Ala Thr Asp Thr Leu Arg Leu Pro Met Thr  
260                265                270  
Pro Ile Thr Asp Ser Gly Arg Glu Thr Val Arg Ala Ala Leu Lys His  
35                275                280                285  
Ala Gly Leu Leu  
290

40                <210> 3  
<211> 2147  
<212> DNA  
<213> Escherichia coli

45                <220>  
<221> CDS  
50                <222> (584)..(1930)

55                <400> 3  
tcgaagtgtt tctgttgtgc ctgccaggca gcggtctgct ttggatttat gtttttcatt 60  
agcaataactc ttctgatttt gagaattgtg actttgaaat atttagcgc cagtcacaga 120

## EP 1 188 822 A1

aaaatgtat ggttttagtg ccgttagcgt aatgttgcgt gtaaaccctt agcgactgta 180  
 agcatttatt agctgaacta ctgaccgcca ggagtggatg aaaaatccgc atgaccccat 240  
 5 cgttgacaac cgccccgctc accctttatt tataaatgtt ctacctgcgc tagcgaggc 300  
 cagaagaggc gcgttgccta agtaacggtg ttggaggagc cagtcctgtg ataacacctg 360  
 agggggtgca tcggcgaggt gattgaacgg ctggccacgt tcatcatcg 420  
 10 tgaatcccct gggttgtcac cagaagcggt cgcagtcgg egttcgcaa gtggtgagc 480  
 acttctgggt gaaaatagta gCGAAGTATC GCTCTGCCTT CCGCTTTCC 540  
 cttgtccaa ggctgaaaat ggatcccctg acacgaggta gtt atg tct gaa att 595

Met Ser Glu Ile

1

gtt gtc tcc aaa ttt ggc ggt acc agc gta gct gat ttt gac gcc atg 643  
 Val Val Ser Lys Phe Gly Gly Thr Ser Val Ala Asp Phe Asp Ala Met

20 5 10 15 20  
 aac cgc agc gct gat att gtg ctt tct gat gcc aac gtg cgt tta gtt 691  
 Asn Arg Ser Ala Asp Ile Val Leu Ser Asp Ala Asn Val Arg Leu Val  
 25 25 30 35

25 gtc ctc tcg gct tct gct ggt atc act aat ctg ctg gtc gct tta gct 739  
 Val Leu Ser Ala Ser Ala Gly Ile Thr Asn Leu Leu Val Ala Leu Ala  
 40 40 45 50

30 gaa gga ctg gaa cct ggc gag cga ttc gaa aaa ctc gac gct atc cgc 787  
 Glu Gly Leu Glu Pro Gly Glu Arg Phe Glu Lys Leu Asp Ala Ile Arg  
 55 55 60 65

35 aac atc cag ttt gcc att ctg gaa cgt ctg cgt tac ccg aac gtt atc 835  
 Asn Ile Gln Phe Ala Ile Leu Glu Arg Leu Arg Tyr Pro Asn Val Ile  
 70 70 75 80

40 cgt gaa gag att gaa cgt ctg ctg gag aac att act gtt ctg gca gaa 883  
 Arg Glu Glu Ile Glu Arg Leu Leu Glu Asn Ile Thr Val Leu Ala Glu  
 85 85 90 95 100

45 gcg gcg gcg ctg gca acg tct ccg gcg ctg aca gat gag ctg gtc agc 931  
 Ala Ala Ala Leu Ala Thr Ser Pro Ala Leu Thr Asp Glu Leu Val Ser  
 105 105 110 115

cac ggc gag ctg atg tcg acc ctg ctg ttt gtt gag atc ctg cgc gaa 979  
 His Gly Glu Leu Met Ser Thr Leu Leu Phe Val Glu Ile Leu Arg Glu  
 120 120 125 130

50 cgc gat gtt cag gca cag tgg ttt gat gta cgt aaa gtg atg cgt acc 1027  
 Arg Asp Val Gln Ala Gln Trp Phe Asp Val Arg Lys Val Met Arg Thr  
 135 135 140 145

55 aac gac cga ttt ggt cgt gca gag cca gat ata gcc gcg ctg gcg gaa 1075

## EP 1 188 822 A1

|    |   |     |     |      |  |
|----|---|-----|-----|------|--|
|    | Asn Asp Arg Phe Gly Arg Ala Glu Pro Asp Ile Ala Ala Leu Ala Glu |     |     |      |  |
| 5  | 150   | 155 | 160 |      |  |
|    | ctg gcc gcg ctg cag ctg ctc cca cgt ctc aat gaa ggc tta gtg atc |     |     | 1123 |  |
|    | Leu Ala Ala Leu Gln Leu Leu Pro Arg Leu Asn Glu Gly Leu Val Ile |     |     |      |  |
| 10 | 165   | 170 | 175 | 180  |  |
|    | acc cag gga ttt atc ggt agc gaa aat aaa ggt cgt aca acg acg ctt |     |     | 1171 |  |
|    | Thr Gln Gly Phe Ile Gly Ser Glu Asn Lys Gly Arg Thr Thr Leu     |     |     |      |  |
|    | 185   | 190 | 195 |      |  |
| 15 | ggc cgt gga ggc agc gat tat acg gca gcc ttg ctg gcg gag gct tta |     |     | 1219 |  |
|    | Gly Arg Gly Gly Ser Asp Tyr Thr Ala Ala Leu Leu Ala Glu Ala Leu |     |     |      |  |
|    | 200   | 205 | 210 |      |  |
| 20 | cac gca tct cgt gtt gat atc tgg acc gac gtc ccg ggc atc tac acc |     |     | 1267 |  |
|    | His Ala Ser Arg Val Asp Ile Trp Thr Asp Val Pro Gly Ile Tyr Thr |     |     |      |  |
|    | 215   | 220 | 225 |      |  |
|    | acc gat cca cgc gta gtt tcc gca gca aaa cgc att gat gaa atc gcg |     |     | 1315 |  |
|    | Thr Asp Pro Arg Val Val Ser Ala Ala Lys Arg Ile Asp Glu Ile Ala |     |     |      |  |
| 25 | 230   | 235 | 240 |      |  |
|    | ttt gcc gaa gcg gca gag atg gca act ttt ggt gca aaa gta ctg cat |     |     | 1363 |  |
|    | Phe Ala Glu Ala Ala Glu Met Ala Thr Phe Gly Ala Lys Val Leu His |     |     |      |  |
| 30 | 245   | 250 | 255 | 260  |  |
|    | ccg gca acg ttg cta ccc gca gta cgc agc gat atc ccg gtc ttt gtc |     |     | 1411 |  |
|    | Pro Ala Thr Leu Leu Pro Ala Val Arg Ser Asp Ile Pro Val Phe Val |     |     |      |  |
|    | 265   | 270 | 275 |      |  |
| 35 | ggc tcc agc aaa gac cca cgc gca ggt ggt acg ctg gtg tgc aat aaa |     |     | 1459 |  |
|    | Gly Ser Ser Lys Asp Pro Arg Ala Gly Gly Thr Leu Val Cys Asn Lys |     |     |      |  |
|    | 280   | 285 | 290 |      |  |
| 40 | act gaa aat ccg ccg ctg ttc cgc gct ctg gcg ctt cgt cgc aat cag |     |     | 1507 |  |
|    | Thr Glu Asn Pro Pro Leu Phe Arg Ala Leu Ala Leu Arg Arg Asn Gln |     |     |      |  |
|    | 295   | 300 | 305 |      |  |
| 45 | act ctg ctc act ttg cac agc ctg aat atg ctg cat tct cgc ggt ttc |     |     | 1555 |  |
|    | Thr Leu Leu Thr Leu His Ser Leu Asn Met Leu His Ser Arg Gly Phe |     |     |      |  |
|    | 310   | 315 | 320 |      |  |
| 50 | ctc gcg gaa gtt ttc ggc atc ctc gcg cgg cat aat att tcg gta gac |     |     | 1603 |  |
|    | Leu Ala Glu Val Phe Gly Ile Leu Ala Arg His Asn Ile Ser Val Asp |     |     |      |  |
|    | 325   | 330 | 335 | 340  |  |
|    | tta atc acc acg tca gaa gtg agc gtc gca tta acc ctt gat acc acc |     |     | 1651 |  |
|    | Leu Ile Thr Thr Ser Glu Val Ser Val Ala Leu Thr Leu Asp Thr Thr |     |     |      |  |
| 55 | 345   | 350 | 355 |      |  |

ggt tca acc tcc act ggc gat acg ttg ctg acg caa tct ctg ctg atg 1699  
 Gly Ser Thr Ser Thr Gly Asp Thr Leu Leu Thr Gln Ser Leu Leu Met  
 5 360 365 370  
 gag ctt tcc gca ctg tgt cgg gtg gag gtg gaa gaa ggt ctg gcg ctg 1747  
 Glu Leu Ser Ala Leu Cys Arg Val Glu Val Glu Glu Gly Leu Ala Leu  
 10 375 380 385  
 gtc gcg ttg att ggc aat gac ctg tca aaa gcc tgc ggc gtt ggc aaa 1795  
 Val Ala Leu Ile Gly Asn Asp Leu Ser Lys Ala Cys Gly Val Gly Lys  
 15 390 395 400  
 gag gta ttc ggc gta ctg gaa ccg ttc aac att cgc atg att tgt tat 1843  
 Glu Val Phe Gly Val Leu Glu Pro Phe Asn Ile Arg Met Ile Cys Tyr  
 405 410 415 420  
 20 ggc gca tcc agc cat aac ctg tgc ttc ctg gtg ccc gcc gaa gat gcc 1891  
 Gly Ala Ser Ser His Asn Leu Cys Phe Leu Val Pro Gly Glu Asp Ala  
 425 430 435  
 gag cag gtg gtg caa aaa ctg cat agt aat ttg ttt gag taaatactgt 1940  
 Glu Gln Val Val Gln Lys Leu His Ser Asn Leu Phe Glu  
 25 440 445  
 atggcctgga agctataattt cggccgtat tgattttttt gtcactatgc tcatcaataa 2000  
 acgagccgtt actctgttaa ccagcgttt tatcggagaa taattgcctt taattttttt 2060  
 30 atctgcatct ctaattaattt atcggaaagag ataaatagtt aagagaaggc aaaatgaata 2120  
 ttatcagttc tgctcgcaaa ggaattc 2147

35 <210> 4  
 <211> 449  
 <212> PRT  
 <213> Escherichia coli

40 <400> 4  
 Met Ser Glu Ile Val Val Ser Lys Phe Gly Gly Thr Ser Val Ala Asp  
 45 1 5 10 15  
 Phe Asp Ala Met Asn Arg Ser Ala Asp Ile Val Leu Ser Asp Ala Asn  
 20 25 30  
 Val Arg Leu Val Val Leu Ser Ala Ser Ala Gly Ile Thr Asn Leu Leu  
 50 35 40 45  
 Val Ala Leu Ala Glu Gly Leu Glu Pro Gly Glu Arg Phe Glu Lys Leu  
 55 50 55 60  
 Asp Ala Ile Arg Asn Ile Gln Phe Ala Ile Leu Glu Arg Leu Arg Tyr

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | 65  | 70  | 75  | 80  |
| 5  | Pro Asn Val Ile Arg Glu Glu Ile Glu Arg Leu Leu Glu Asn Ile Thr |     |     |     |
|    | 85  | 90  | 95  |     |
| 10 | Val Leu Ala Glu Ala Ala Ala Leu Ala Thr Ser Pro Ala Leu Thr Asp |     |     |     |
|    | 100   | 105 | 110 |     |
| 15 | Glu Leu Val Ser His Gly Glu Leu Met Ser Thr Leu Leu Phe Val Glu |     |     |     |
|    | 115   | 120 | 125 |     |
| 20 | Ile Leu Arg Glu Arg Asp Val Gln Ala Gln Trp Phe Asp Val Arg Lys |     |     |     |
|    | 130   | 135 | 140 |     |
| 25 | Val Met Arg Thr Asn Asp Arg Phe Gly Arg Ala Glu Pro Asp Ile Ala |     |     |     |
|    | 145   | 150 | 155 | 160 |
| 30 | Ala Leu Ala Glu Leu Ala Ala Leu Gln Leu Leu Pro Arg Leu Asn Glu |     |     |     |
|    | 165   | 170 | 175 |     |
| 35 | Gly Leu Val Ile Thr Gln Gly Phe Ile Gly Ser Glu Asn Lys Gly Arg |     |     |     |
|    | 180   | 185 | 190 |     |
| 40 | Thr Thr Thr Leu Gly Arg Gly Ser Asp Tyr Thr Ala Ala Leu Leu     |     |     |     |
|    | 195   | 200 | 205 |     |
| 45 | Ala Glu Ala Leu His Ala Ser Arg Val Asp Ile Trp Thr Asp Val Pro |     |     |     |
|    | 210   | 215 | 220 |     |
| 50 | Gly Ile Tyr Thr Thr Asp Pro Arg Val Val Ser Ala Ala Lys Arg Ile |     |     |     |
|    | 225   | 230 | 235 | 240 |
| 55 | Asp Glu Ile Ala Phe Ala Glu Ala Ala Glu Met Ala Thr Phe Gly Ala |     |     |     |
|    | 245   | 250 | 255 |     |
| 60 | Lys Val Leu His Pro Ala Thr Leu Leu Pro Ala Val Arg Ser Asp Ile |     |     |     |
|    | 260   | 265 | 270 |     |
| 65 | Pro Val Phe Val Gly Ser Ser Lys Asp Pro Arg Ala Gly Gly Thr Leu |     |     |     |
|    | 275   | 280 | 285 |     |
| 70 | Val Cys Asn Lys Thr Glu Asn Pro Pro Leu Phe Arg Ala Leu Ala Leu |     |     |     |
|    | 290   | 295 | 300 |     |
| 75 | Arg Arg Asn Gln Thr Leu Leu Thr Leu His Ser Leu Asn Met Leu His |     |     |     |
|    | 305   | 310 | 315 | 320 |
| 80 | Ser Arg Gly Phe Leu Ala Glu Val Phe Gly Ile Leu Ala Arg His Asn |     |     |     |
|    | 325   | 330 | 335 |     |
| 85 | Ile Ser Val Asp Leu Ile Thr Thr Ser Glu Val Ser Val Ala Leu Thr |     |     |     |
|    | 340   | 345 | 350 |     |
| 90 | Leu Asp Thr Thr Gly Ser Thr Ser Thr Gly Asp Thr Leu Leu Thr Gln |     |     |     |
|    | 355   | 360 | 365 |     |
| 95 | Ser Leu Leu Met Glu Leu Ser Ala Leu Cys Arg Val Glu Val Glu Glu |     |     |     |

370                    375                    380  
 Gly Leu Ala Leu Val Ala Leu Ile Gly Asn Asp Leu Ser Lys Ala Cys  
 5                    385                    390                    395                    400  
 Gly Val Gly Lys Glu Val Phe Gly Val Leu Glu Pro Phe Asn Ile Arg  
 10                    405                    410                    415  
 Met Ile Cys Tyr Gly Ala Ser Ser His Asn Leu Cys Phe Leu Val Pro  
 15                    420                    425                    430  
 Gly Glu Asp Ala Glu Gln Val Val Gln Lys Leu His Ser Asn Leu Phe  
 20                    435                    440                    445  
 25                    Glu

20                    <210> 5  
 <211> 1981  
 <212> DNA  
 25                    <213> *Methylophilus methylotrophus*

30                    <220>  
 <221> CDS  
 35                    <222> (510)..(1736)

40                    <400> 5  
 gtttaacgca gccagtgaat ttgactcggt cccctgcctg gcaaaatcgc acaggtgatg 60  
 45                    gacaacgtga aatcgcttga aaaagaattt gcacgcctca agtccaagct ggcctcctca 120  
 cagggggatg acctcgccac gcaagcgcag gacgtcaacg ggccttgc 180  
 accctcgacg gggcgatgc caatgccttgc cgtaaaaacca tggataagct caaaagataaaa 240  
 ctcaaattctg cagtcattgt gctggcgagc gtggctgacg gtaaagtctg 300  
 50                    ggtgtcaact ctgacttgac tggcaagggtc aaaggcaggcg aagttggtca atcatgtggc 360  
 tggtcagggtc ggtggcaaaat gtgggtgtaa accggatatg gcatggcag gtggtaactga 420  
 gcccgtataat ttggcgcaagg ctttggcaag tgtgaaggct tggtagaaaa caaaaactaaaa 480  
 55                    ttaatttaat tgattaacag agcggaaata atg gca tta atc gta caa aaa tat 533  
 Met Ala Leu Ile Val Gln Lys Tyr

1                    5

50                    ggt ggt acc tcg gtg gct aat ccc gag cgt atc cgt aat gtg gcg cgt 581  
 Gly Gly Thr Ser Val Ala Asn Pro Glu Arg Ile Arg Asn Val Ala Arg  
 55                    10                    15                    20  
 cgc gtg gcg cgt tac aag gca ttg ggc cac cag gtg gtg gtt gtg gta 629  
 Arg Val Ala Arg Tyr Lys Ala Leu Gly His Gln Val Val Val Val

## EP 1 188 822 A1

|   |     |     |     |      |
|---|-----|-----|-----|------|
| 25  | 30  | 35  | 40  |      |
| tcc gca atg tct ggt gaa acc aac cgg ttg atc tca ctg gcc aag gaa |     |     |     | 677  |
| Ser Ala Met Ser Gly Glu Thr Asn Arg Leu Ile Ser Leu Ala Lys Glu |     |     |     |      |
| 45  | 50  | 55  |     |      |
| atc atg caa gac cct gat cca cgt gag ctg gat gtg atg gta tca acc |     |     |     | 725  |
| Ile Met Gln Asp Pro Asp Pro Arg Glu Leu Asp Val Met Val Ser Thr |     |     |     |      |
| 10 60   | 65  | 70  |     |      |
| ggt gag cag gtc acc atc ggc atg acg gcc ctg gca ctg atg gag ctt |     |     |     | 773  |
| Gly Glu Gln Val Thr Ile Gly Met Thr Ala Leu Ala Leu Met Glu Leu |     |     |     |      |
| 15 75   | 80  | 85  |     |      |
| ggc att aag gca aaa agc tat acc ggt acc cag gtt aag atc ttg act |     |     |     | 821  |
| Gly Ile Lys Ala Lys Ser Tyr Thr Gly Thr Gln Val Lys Ile Leu Thr |     |     |     |      |
| 20 90   | 95  | 100 |     |      |
| gac gat gct ttt acc aag gca cgt att ctg gat atc gac gaa cat aac |     |     |     | 869  |
| Asp Asp Ala Phe Thr Lys Ala Arg Ile Leu Asp Ile Asp Glu His Asn |     |     |     |      |
| 105 110   | 115 | 120 |     |      |
| ctg aaa aaa gac ctg gat gat ggc tat gtc tgc gtg gtg gct ggg ttc |     |     |     | 917  |
| Leu Lys Lys Asp Leu Asp Asp Gly Tyr Val Cys Val Val Ala Gly Phe |     |     |     |      |
| 25 125  | 130 | 135 |     |      |
| cag ggc gtg gat gcc aat ggc aat att acg acc ttg ggc cgt ggc ggc |     |     |     | 965  |
| Gln Gly Val Asp Ala Asn Gly Asn Ile Thr Thr Leu Gly Arg Gly Gly |     |     |     |      |
| 30 140  | 145 | 150 |     |      |
| tca gat act act ggt gta gca ctg gct gcg gcg tta aag gcg gat gaa |     |     |     | 1013 |
| Ser Asp Thr Thr Gly Val Ala Ala Ala Leu Lys Ala Asp Glu         |     |     |     |      |
| 35 155  | 160 | 165 |     |      |
| tgt cag att tat acc gat gtc gat ggc gtt tac acc acc gat ccg cgt |     |     |     | 1061 |
| Cys Gln Ile Tyr Thr Asp Val Asp Gly Val Tyr Thr Asp Pro Arg     |     |     |     |      |
| 40 170  | 175 | 180 |     |      |
| gtg gtg cct gag gca cgc cgc ttg gat aaa att acc ttt gaa gaa atg |     |     |     | 1109 |
| Val Val Pro Glu Ala Arg Arg Leu Asp Lys Ile Thr Phe Glu Glu Met |     |     |     |      |
| 45 185  | 190 | 195 | 200 |      |
| ttg gaa ctg gct tca cag ggc tcc aaa gta ttg caa att cgc tcg gtt |     |     |     | 1157 |
| Leu Glu Leu Ala Ser Gln Gly Ser Lys Val Leu Gln Ile Arg Ser Val |     |     |     |      |
| 50 205  | 210 | 215 |     |      |
| gag ttt gcc ggt aaa tac aaa gtc aaa tta cgt gtg ctg tcc agc ttc |     |     |     | 1205 |
| Glu Phe Ala Gly Lys Tyr Lys Val Lys Leu Arg Val Leu Ser Ser Phe |     |     |     |      |
| 55 220  | 225 | 230 |     |      |
| gaa gag gag ggc gac ggt aca ctg atc aca ttc gaa gaa aat gag gaa |     |     |     | 1253 |

Glu Glu Glu Gly Asp Gly Thr Leu Ile Thr Phe Glu Glu Asn Glu Glu  
 235 240 245  
 5 aac atg gaa gaa cca att atc tcc ggc atc gcc ttt aac cgc gat gag 1301  
 Asn Met Glu Glu Pro Ile Ile Ser Gly Ile Ala Phe Asn Arg Asp Glu  
 250 255 260  
 10 gcg aaa att acc gtg acg ggc gtg ccc gac aaa cca gga att gcc tat 1349  
 Ala Lys Ile Thr Val Thr Gly Val Pro Asp Lys Pro Gly Ile Ala Tyr  
 265 270 275 280  
 15 cag att ttg ggc ccg gtg gca gac gcc aat att gat gtg gat atg att 1397  
 Gln Ile Leu Gly Pro Val Ala Asp Ala Asn Ile Asp Val Asp Met Ile  
 285 290 295  
 20 atc cag aac gtc ggt gcg gat ggt acg act gac ttc acc ttt acc gta 1445  
 Ile Gln Asn Val Gly Ala Asp Gly Thr Thr Asp Phe Thr Phe Thr Val  
 300 305 310  
 cat aaa aat gag atg aac aaa gcc ctg agc att ctt aga gat aaa gtg 1493  
 His Lys Asn Glu Met Asn Lys Ala Leu Ser Ile Leu Arg Asp Lys Val  
 25 315 320 325  
 30 cag ggc cat atc cag gca cgt gaa atc agc ggc gac gac aag att gcc 1541  
 Gln Gly His Ile Gln Ala Arg Glu Ile Ser Gly Asp Asp Lys Ile Ala  
 330 335 340  
 35 aaa gtc tct gtg gtt ggg gtg ggt atg cgc tca cat gta ggg atc gcc 1589  
 Lys Val Ser Val Val Gly Val Gly Met Arg Ser His Val Gly Ile Ala  
 345 350 355 360  
 40 agc cag atg ttc cgt acg ctg gcc gaa gaa ggg atc aat att caa atg 1637  
 Ser Gln Met Phe Arg Thr Leu Ala Glu Glu Gly Ile Asn Ile Gln Met  
 365 370 375  
 45 atc tca acc agc gaa att aaa att gca gtc gtg atc gaa gag aag tac 1685  
 Ile Ser Thr Ser Glu Ile Lys Ile Ala Val Val Ile Glu Glu Lys Tyr  
 380 385 390  
 50 atg gaa ctg gct gta cgc gtg ttg cat aaa gca ttc ggc ctc gaa aac 1733  
 Met Glu Leu Ala Val Arg Val Leu His Lys Ala Phe Gly Leu Glu Asn  
 395 400 405  
 gca taatcgccaa cggacgaata aagaataaaa acatttttctt tttttgcgtt 1786  
 Ala  
 55 gattttgaa gggttttcac gtatgtggc agcccttgc tgcatgtca atgctgcaaa 1846  
 gagaacagca tgccgtgt ttggactat taaaacttca ttgtttaat aaggtgaggg 1906  
 ggatcctcta gagtcgacct gcaggcatgc aagcttgccc gtaatccatg gtcatacg 1966  
 tttcctggtg tgaaa 1981

&lt;210&gt; 6

&lt;211&gt; 409

5 &lt;212&gt; PRT

&lt;213&gt; Methylophilus methylotrophus

10 &lt;400&gt; 6

Met Ala Leu Ile Val Gln Lys Tyr Gly Gly Thr Ser Val Ala Asn Pro

1 5 10 15

Glu Arg Ile Arg Asn Val Ala Arg Arg Val Ala Arg Tyr Lys Ala Leu

15 20 25 30

Gly His Gln Val Val Val Val Ser Ala Met Ser Gly Glu Thr Asn

35 40 45

Arg Leu Ile Ser Leu Ala Lys Glu Ile Met Gln Asp Pro Asp Pro Arg

20 50 55 60

Glu Leu Asp Val Met Val Ser Thr Gly Glu Gln Val Thr Ile Gly Met

25 65 70 75 80

Thr Ala Leu Ala Leu Met Glu Leu Gly Ile Lys Ala Lys Ser Tyr Thr

85 90 95

Gly Thr Gln Val Lys Ile Leu Thr Asp Asp Ala Phe Thr Lys Ala Arg

30 100 105 110

Ile Leu Asp Ile Asp Glu His Asn Leu Lys Lys Asp Leu Asp Asp Gly

115 120 125

Tyr Val Cys Val Val Ala Gly Phe Gln Gly Val Asp Ala Asn Gly Asn

35 130 135 140

Ile Thr Thr Leu Gly Arg Gly Ser Asp Thr Thr Gly Val Ala Leu

40 145 150 155 160

Ala Ala Ala Leu Lys Ala Asp Glu Cys Gln Ile Tyr Thr Asp Val Asp

165 170 175

Gly Val Tyr Thr Thr Asp Pro Arg Val Val Pro Glu Ala Arg Arg Leu

45 180 185 190

Asp Lys Ile Thr Phe Glu Glu Met Leu Glu Leu Ala Ser Gln Gly Ser

195 200 205

Lys Val Leu Gln Ile Arg Ser Val Glu Phe Ala Gly Lys Tyr Lys Val

50 210 215 220

Lys Leu Arg Val Leu Ser Ser Phe Glu Glu Glu Gly Asp Gly Thr Leu

225 230 235 240

Ile Thr Phe Glu Glu Asn Glu Asn Met Glu Glu Pro Ile Ile Ser

55

## EP 1 188 822 A1

|    |   |     |     |
|----|---|-----|-----|
|    | 245   | 250 | 255 |
| 5  | Gly Ile Ala Phe Asn Arg Asp Glu Ala Lys Ile Thr Val Thr Gly Val |     |     |
|    | 260   | 265 | 270 |
|    | Pro Asp Lys Pro Gly Ile Ala Tyr Gln Ile Leu Gly Pro Val Ala Asp |     |     |
|    | 275   | 280 | 285 |
| 10 | Ala Asn Ile Asp Val Asp Met Ile Ile Gln Asn Val Gly Ala Asp Gly |     |     |
|    | 290   | 295 | 300 |
|    | Thr Thr Asp Phe Thr Phe Thr Val His Lys Asn Glu Met Asn Lys Ala |     |     |
|    | 305   | 310 | 315 |
| 15 | Leu Ser Ile Leu Arg Asp Lys Val Gln Gly His Ile Gln Ala Arg Glu |     |     |
|    | 325   | 330 | 335 |
|    | Ile Ser Gly Asp Asp Lys Ile Ala Lys Val Ser Val Val Gly Val Gly |     |     |
| 20 | 340   | 345 | 350 |
|    | Met Arg Ser His Val Gly Ile Ala Ser Gln Met Phe Arg Thr Leu Ala |     |     |
|    | 355   | 360 | 365 |
| 25 | Glu Glu Gly Ile Asn Ile Gln Met Ile Ser Thr Ser Glu Ile Lys Ile |     |     |
|    | 370   | 375 | 380 |
|    | Ala Val Val Ile Glu Glu Lys Tyr Met Glu Leu Ala Val Arg Val Leu |     |     |
|    | 385   | 390 | 395 |
| 30 | His Lys Ala Phe Gly Leu Glu Asn Ala                             |     |     |
|    | 405   |     |     |

&lt;210&gt; 7

&lt;211&gt; 1452

&lt;212&gt; DNA

&lt;213&gt; Methylophilus methylotrophus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (98)..(1207)

45

&lt;400&gt; 7

gcatgccgc aggtcgactc tagaggatcc ccctgttcaa aaatcttcca aataatcact 60

50 gtaatgccgg gttgtccggc taaaaatatcg agtcact atg tta aaa gta ggg ttt 115

Met Leu Lys Val Gly Phe

1 5

gta ggc tgg cgt ggc atg gtt gga tcc gtg cta atg cag cgc atg atg 163

55 Val Gly Trp Arg Gly Met Val Gly Ser Val Leu Met Gln Arg Met Met

## EP 1 188 822 A1

|    |  |     |     |     |
|----|--|-----|-----|-----|
|    | 10   | 15  | 20  |     |
| 5  | cag gaa aac gat ttt gcg gat att gaa ccg caa ttc ttt acg acc tca<br>Gln Glu Asn Asp Phe Ala Asp Ile Glu Pro Gln Phe Phe Thr Thr Ser |     |     | 211 |
|    | 25   | 30  | 35  |     |
| 10 | caa acg gga ggg gct gcg cct aaa gtt gga aaa gat act cct gcg ctg<br>Gln Thr Gly Gly Ala Ala Pro Lys Val Gly Lys Asp Thr Pro Ala Leu |     |     | 259 |
|    | 40   | 45  | 50  |     |
| 15 | aaa gat gcc aag gat att gat gct ttg cgc cag atg gat gtg att gtg<br>Lys Asp Ala Lys Asp Ile Asp Ala Leu Arg Gln Met Asp Val Ile Val |     |     | 307 |
|    | 55   | 60  | 65  | 70  |
| 20 | acc tgc cag ggt ggc gat tac acg agt gac gtc ttc cca caa ttg cgc<br>Thr Cys Gln Gly Gly Asp Tyr Thr Ser Asp Val Phe Pro Gln Leu Arg |     |     | 355 |
|    | 75   | 80  | 85  |     |
| 25 | gca acc ggc tgg agc ggc cac tgg att gac gcg gcc tct acc tta cgc<br>Ala Thr Gly Trp Ser Gly His Trp Ile Asp Ala Ala Ser Thr Leu Arg |     |     | 403 |
|    | 90   | 95  | 100 |     |
| 30 | atg gaa aaa gac tcc gtg atc att tta gac ccg gtg aac atg cat gtg<br>Met Glu Lys Asp Ser Val Ile Ile Leu Asp Pro Val Asn Met His Val |     |     | 451 |
|    | 105  | 110 | 115 |     |
| 35 | att aaa gat gca ttg tcc aat ggc ggc aaa aac tgg atc ggc ggc aac<br>Ile Lys Asp Ala Leu Ser Asn Gly Gly Lys Asn Trp Ile Gly Gly Asn |     |     | 499 |
|    | 120  | 125 | 130 |     |
| 40 | tgt acc gtc tca ctt atg ttg atg gcg ctg aat ggc ctg ttt aag gct<br>Cys Thr Val Ser Leu Met Leu Met Ala Leu Asn Gly Leu Phe Lys Ala |     |     | 547 |
|    | 135  | 140 | 145 | 150 |
| 45 | gac ctg gtc gag tgg gcc act tcc atg acc tac cag gcg gct tca ggc<br>Asp Leu Val Glu Trp Ala Thr Ser Met Thr Tyr Gln Ala Ala Ser Gly |     |     | 595 |
|    | 155  | 160 | 165 |     |
| 50 | gca ggc gcg cag aat atg cgt gaa ctg att agc cag atg ggc gta gtg<br>Ala Gly Ala Gln Asn Met Arg Glu Leu Ile Ser Gln Met Gly Val Val |     |     | 643 |
|    | 170  | 175 | 180 |     |
| 55 | aat gcc tcc gtg gct gat ttg ctg gcg gat cca gct tct gcc att ttg<br>Asn Ala Ser Val Ala Asp Leu Leu Ala Asp Pro Ala Ser Ala Ile Leu |     |     | 691 |
|    | 185  | 190 | 195 |     |
| 60 | cag atc gat aaa aca gtg gcg gat acc atc cgt agc gaa gag ttg cct<br>Gln Ile Asp Lys Thr Val Ala Asp Thr Ile Arg Ser Glu Glu Leu Pro |     |     | 739 |
|    | 200  | 205 | 210 |     |
| 65 | aaa tct aac ttt ggt gtg cca ttg gcg ggc agt ctg atc cca tgg atc  |     |     | 787 |

## EP 1 188 822 A1

Lys Ser Asn Phe Gly Val Pro Leu Ala Gly Ser Leu Ile Pro Trp Ile  
 215                    220                    225                    230  
 5 gac aag gac tta ggg aat ggt caa agt aaa gaa gaa tgg aag ggc ggc    835  
 Asp Lys Asp Leu Gly Asn Gly Gln Ser Lys Glu Glu Trp Lys Gly Gly  
 235                    240                    245  
 10 gta nag acc aat aag att tta ggt cgt gaa gcg aac ccg att gtg att    883  
 Val Xaa Thr Asn Lys Ile Leu Gly Arg Glu Ala Asn Pro Ile Val Ile  
 250                    255                    260  
 15 gac ggt ttg tgt gta cgt atc ggc gcc atg cgt tgc cat tca caa gcg    931  
 Asp Gly Leu Cys Val Arg Ile Gly Ala Met Arg Cys His Ser Gln Ala  
 265                    270                    275  
 20 ttg act atc aag ctg cgc aag gat gtg ccg ctg gat gaa atc aat cag    979  
 Leu Thr Ile Lys Leu Arg Lys Asp Val Pro Leu Asp Glu Ile Asn Gln  
 280                    285                    290  
 25 atg ctg gct gaa gcg aac gac tgg gct aaa gtc att ccc aat gag cgt    1027  
 Met Leu Ala Glu Ala Asn Asp Trp Ala Lys Val Ile Pro Asn Glu Arg  
 295                    300                    305                    310  
 30 gag gtc agt atg cgg gaa ctc acc ccg gca gcg att acc ggc agt ctg    1075  
 Glu Val Ser Met Arg Glu Leu Thr Pro Ala Ala Ile Thr Gly Ser Leu  
 315                    320                    325  
 gcg acg cca gta ggg cgt ttg cgc aaa ctg gcg atg ggt ggt gaa tac    1123  
 Ala Thr Pro Val Gly Arg Leu Arg Lys Leu Ala Met Gly Gly Glu Tyr  
 330                    335                    340  
 35 ttg tcg gca ttt acc gta ggt gac cag ttg tta tgg ggc gct gcc gaa    1171  
 Leu Ser Ala Phe Thr Val Gly Asp Gln Leu Leu Trp Gly Ala Ala Glu  
 345                    350                    355  
 40 cct ttg cgc aga atg ttg agg att ctg gtc gaa tct taagtattt        1217  
 Pro Leu Arg Arg Met Leu Arg Ile Leu Val Glu Ser  
 360                    365                    370  
 45 tttaagtagc agcccgtaaa gctatgattt atcaataaaa tcatggtctt ttccggcttt 1277  
 tgcttttgt gcaatcctgt ttaatggta ttgttagcctc aaatcctgta tttattgctc 1337  
 tcaageccgc tgggtgcgt tgegtggctg ggtgaatgat gctatttga caaacgccat 1397  
 gaattactaa gggttaatcg gtgagtaaat ttcaattaaa aaaaatagcc ttgac    1452  
 50 <210> 8  
 <211> 370  
 <212> PRT  
 55 <213> Methylophilus methylotrophus

## EP 1 188 822 A1

&lt;400&gt; 8

Met Leu Lys Val Gly Phe Val Gly Trp Arg Gly Met Val Gly Ser Val  
 1 5 10 15

Leu Met Gln Arg Met Met Gln Glu Asn Asp Phe Ala Asp Ile Glu Pro  
 20 25 30

Gln Phe Phe Thr Thr Ser Gln Thr Gly Gly Ala Ala Pro Lys Val Gly  
 35 40 45

Lys Asp Thr Pro Ala Leu Lys Asp Ala Lys Asp Ile Asp Ala Leu Arg  
 50 55 60

Gln Met Asp Val Ile Val Thr Cys Gln Gly Gly Asp Tyr Thr Ser Asp  
 65 70 75 80

Val Phe Pro Gln Leu Arg Ala Thr Gly Trp Ser Gly His Trp Ile Asp  
 85 90 95

Ala Ala Ser Thr Leu Arg Met Glu Lys Asp Ser Val Ile Ile Leu Asp  
 100 105 110

Pro Val Asn Met His Val Ile Lys Asp Ala Leu Ser Asn Gly Gly Lys  
 115 120 125

Asn Trp Ile Gly Gly Asn Cys Thr Val Ser Leu Met Leu Met Ala Leu  
 130 135 140

Asn Gly Leu Phe Lys Ala Asp Leu Val Glu Trp Ala Thr Ser Met Thr  
 145 150 155 160

Tyr Gln Ala Ala Ser Gly Ala Gly Ala Gln Asn Met Arg Glu Leu Ile  
 165 170 175

Ser Gln Met Gly Val Val Asn Ala Ser Val Ala Asp Leu Leu Ala Asp  
 180 185 190

Pro Ala Ser Ala Ile Leu Gln Ile Asp Lys Thr Val Ala Asp Thr Ile  
 195 200 205

Arg Ser Glu Glu Leu Pro Lys Ser Asn Phe Gly Val Pro Leu Ala Gly  
 210 215 220

Ser Leu Ile Pro Trp Ile Asp Lys Asp Leu Gly Asn Gly Gln Ser Lys  
 225 230 235 240

Glu Glu Trp Lys Gly Gly Val Xaa Thr Asn Lys Ile Leu Gly Arg Glu  
 245 250 255

Ala Asn Pro Ile Val Ile Asp Gly Leu Cys Val Arg Ile Gly Ala Met  
 260 265 270

Arg Cys His Ser Gln Ala Leu Thr Ile Lys Leu Arg Lys Asp Val Pro  
 275 280 285

Leu Asp Glu Ile Asn Gln Met Leu Ala Glu Ala Asn Asp Trp Ala Lys

290 295 300

5 Val Ile Pro Asn Glu Arg Glu Val Ser Met Arg Glu Leu Thr Pro Ala.

305 310 315 320

Ala Ile Thr Gly Ser Leu Ala Thr Pro Val Gly Arg Leu Arg Lys Leu

10 325 330 335

Ala Met Gly Gly Glu Tyr Leu Ser Ala Phe Thr Val Gly Asp Gln Leu

340 345 350

Leu Trp Gly Ala Ala Glu Pro Leu Arg Arg Met Leu Arg Ile Leu Val

15 355 360 365

Glu Ser

370

20 <210> 9

<211> 3098

<212> DNA

25 <213> Methylophilus methylotrophus

<220>

30 <221> CDS

<222> (1268)..(2155)

<400> 9

35 cgtgccaact tgcattgcctg ccggtcgctc tagaggatca attgctggca acatttgagt 60

acatttattcg ctttgcatt gtaaaaggcct atggctttga tgtaactttc aagacctgcc 120

agccccaaat ccagatagc ctgcgggtgt ttggccacct tgaacaattt gcgggtggca 180

atattgacac ctttgtctgt cgcctgtgca gacaagatga cggcaatcag taattcgaac 240

gtggagctat gtcaggcgc agtgggttga ttggggatgg cttggggccag ccgctcaaata 300

atgcgcagtc tttttgtgc attcataaaa cggttcaat cataggtcac agggtcaacc 360

tgtctttgc gcttgcacgc gcccattggc tgcggcaatg gcattttct tgagcacctc 420

agttgaggggt gtctcggtcg tagcaagcgt ctgggtgcgt ttgctgttagg ttggcggt 480

ctcccggtt tcaagggcga ggccgagaaag gggttgcgtt tggcgttgc tcgctaccgc 540

ggcttcagct tcattcatgg cggtagcccg accggaaatc gtttgcacat gtatgcagtc 600

caccgggcag ggccgttaaac atagctcaca gccagtgcac tcctggaaa tcaccgtatg 660

catcagtttgc gatgcgcacca aaatggcatac aacgggacag gcctgtatac acagggtgca 720

gccgatgcac gtttccatcat caatcaaggc caccgcatttgc gtttggta tgccgtggc 780

cggtttaat gcctggaaag gacgttgcag taatttggca agcgcataa tgccgcattc 840

tcctccaggc ggacatttgtt tgatattggc ctctccgcgg gcgatgcattt cagcataagg 900

tttgcateccc tcgtaaccgc attggcggca ttgagttgc ggtaataccg cgtcgatctt 960  
 tgcaatgagg tcgacaaaagc gttctggcag ctcaaggcgca gtcgcattcgaa cttcaatcat 1020  
 5 gtgatggcag gtgagttgc attcggtctt ggctaaatag ccgtttaaga tgggttgcta 1080  
 agagtttat tataaccgaa accttgcctt tcctttggcc gggagctagg cggaaaaaagc 1140  
 10 ttgccgcagt tgggtgccag tgatttgcc gccgtcttc gcttgtatcc gtccagatac 1200  
 agcaagttagg cgcgttctt ggcgttagac cggataatca gttaaaatat tcgttttatt 1260  
 cttaaaag atg gcg cta ggt atg tta acg ggc agt ttg gtc gca atc gtg 1309  
 Met Ala Leu Gly Met Leu Thr Gly Ser Leu Val Ala Ile Val  
 1 5 10  
 15 acc ccc atg ttt gaa gat gga cgt ttg gat ctg gac gcc ctc aaa aag 1357  
 Thr Pro Met Phe Glu Asp Gly Arg Leu Asp Leu Asp Ala Leu Lys Lys  
 20 15 20 25 30  
 25 ctg gtc gac ttt cat gta gag gca ggg aca gat ggt att gtc atc gtt 1405  
 Leu Val Asp Phe His Val Glu Ala Gly Thr Asp Gly Ile Val Ile Val  
 30 35 40 45  
 35 ggc acg act ggc gag tcg ccc acg gtc gat gta gat gag cat tgt ctg 1453  
 Gly Thr Thr Gly Glu Ser Pro Thr Val Asp Val Asp Glu His Cys Leu  
 40 50 55 60  
 45 ctg atc aaa acc acg atc gag cat gtc gcc aag cgc gtc cca gtc att 1501  
 Leu Ile Lys Thr Thr Ile Glu His Val Ala Lys Arg Val Pro Val Ile  
 50 55 60  
 55 65 70 75  
 60 gcc ggt act ggc gca aat tcc act gct gaa gcc att gaa ctg act gcc 1549  
 Ala Gly Thr Gly Ala Asn Ser Thr Ala Glu Ala Ile Glu Leu Thr Ala  
 65 80 85 90  
 65 aag gcc aag gcg ctt ggc gca gac gcc tgc ctg ctg gca ccg tat 1597  
 Lys Ala Lys Ala Leu Gly Ala Asp Ala Cys Leu Leu Val Ala Pro Tyr  
 70 95 100 105 110  
 75 tac aac aag ccc tcg caa gag ggt ttg tac cag cac ttt aaa gcc gtc 1645  
 Tyr Asn Lys Pro Ser Gln Glu Gly Leu Tyr Gln His Phe Lys Ala Val  
 80 115 120 125  
 80 gct gag gcg gtc gat att ccg caa att ctc tat aat gtc cca gcc cgc 1693  
 Ala Glu Ala Val Asp Ile Pro Gln Ile Leu Tyr Asn Val Pro Gly Arg  
 85 130 135 140  
 90 acc ggt tgc gac ttg tct aac gac acc gta ttg cgc ctg gcg cag att 1741  
 Thr Gly Cys Asp Leu Ser Asn Asp Thr Val Leu Arg Leu Ala Gln Ile  
 95 145 150 155  
 100 cgc aac att gtc ggg att aag gat ggc act gga ggg att gag cgc ggt 1789  
 Arg Asn Ile Val Gly Ile Lys Asp Ala Thr Gly Gly Ile Glu Arg Gly

|    |  |     |     |      |
|----|--|-----|-----|------|
|    | 160  | 165 | 170 |      |
| 5  | acc gat ttg ttg ttg cgt gca cca gct gat ttc gcc att tac agc ggg    |     |     | 1837 |
|    | Thr Asp Leu Leu Leu Arg Ala Pro Ala Asp Phe Ala Ile Tyr Ser Gly    |     |     |      |
| 10 | 175  | 180 | 185 | 190  |
|    | gat gat gcc act gcg ctg gcc ctg atg tta tta ggg ggg aaa ggc gtg    |     |     | 1885 |
|    | Asp Asp Ala Thr Ala Leu Ala Leu Met Leu Leu Gly Gly Lys Gly Val    |     |     |      |
| 15 | 195  | 200 | 205 |      |
|    | att tcg gtc acg gcc aat gtc gcg ccc aaa tta atg cat gaa atg tgc    |     |     | 1933 |
|    | Ile Ser Val Thr Ala Asn Val Ala Pro Lys Leu Met His Glu Met Cys    |     |     |      |
| 20 | 210  | 215 | 220 |      |
|    | gag cat gct ttg aat ggc aac ctg gcc gca gcc aaa gcg gcc aat gcc    |     |     | 1981 |
|    | Glu His Ala Leu Asn Gly Asn Leu Ala Ala Lys Ala Ala Asn Ala        |     |     |      |
| 25 | 225  | 230 | 235 |      |
|    | aaa ctg ttt gca ttg cac cag aag ttg ttt gta gaa gcg aac ccg att    |     |     | 2029 |
|    | Lys Leu Phe Ala Leu His Gln Lys Leu Phe Val Glu Ala Asn Pro Ile    |     |     |      |
| 30 | 240  | 245 | 250 |      |
|    | cca gtg aaa tgg gta tta caa caa atg gga atg att gcc act ggc atc    |     |     | 2077 |
|    | Pro Val Lys Trp Val Leu Gln Gln Met Gly Met Ile Ala Thr Gly Ile    |     |     |      |
| 35 | 255  | 260 | 265 | 270  |
|    | cgt ttg ccg ctg gtc aat tta tcc agc caa tat cat gaa gta ttg cgc    |     |     | 2125 |
|    | Arg Leu Pro Leu Val Asn Leu Ser Ser Gln Tyr His Glu Val Leu Arg    |     |     |      |
| 40 | 275  | 280 | 285 |      |
|    | aac gcc atg aag cag gca gaa att gcc gct tgatcggtcta aaactaattt     |     |     | 2175 |
|    | Asn Ala Met Lys Gln Ala Glu Ile Ala Ala                            |     |     |      |
| 45 | 290  | 295 |     |      |
|    | agggtgaaac aagtgaaata catgagtcat gtttgttac aacgttttgt gctggccagt   |     |     | 2235 |
|    | ctggtcacag cgcttcagc gtgcgattcc atcccgtta ttgataatag ttctgactac    |     |     | 2295 |
| 50 | aagggcgcag gtcgctccag gccacttgaa gtgcgcgcag acctgaccgc ggtgcgtacc  |     |     | 2355 |
|    | agcagtactt acaatgtgcc tggtagcacc agttactctg cctatagccaa gaaccaggaa |     |     | 2415 |
|    | gtgcaagagc agaatggtcc acagcctgtg ctgcagata tgaaaaacgt ggcgcattgg   |     |     | 2475 |
| 55 | aaagcagggc agcagcggtt gctgggtgtc aatgcgcctc cgaaaaaat ctggccgatt   |     |     | 2535 |
|    | gtgcgtgatt tctggctgga tcaaggcttt gctgtcaggg tagagaatcc tgagcttggc  |     |     | 2595 |
|    | gtgattgaaa ccgagtggtt gcaatctgat gccatcaagc ctaaggaaga taaccgtggc  |     |     | 2655 |
|    | tatggtgaaa agtttgatgc ctggctggat aaactttctg gttttgccga caggcgtaaa  |     |     | 2715 |
|    | ttccgtacgc gtctggAACG tggggagaaaa gacggcacca ccgaaatcta tatgacgcac |     |     | 2775 |
|    | cgtactgtcg ccgggcacc ggatgtggc aaaaattatg tgcagaccca attgggtgtc    |     |     | 2835 |
|    | attgataccg gttatcgccc caacgcggct gaaaacaaga acaatgccgg taaagagttt  |     |     | 2895 |
|    | gatgctgact tggatgcaga attactccgt cgaatgtgg tgaaattagg tctggatgag   |     |     | 2955 |

cagaaaggcag accaggtgat ggcacaatct gcttcagaca agcgtgcaga tgtggtcaag 3015  
 gagtctgacc agagcgtcac cttgaagttg aatgagccgt ttgaccgtgc ctggcgccgt 3075  
 5 gtggcctggc ctggatcccc ggg 3098

<210> 10

<211> 296

<212> PRT

<213> Methylophilus methylotrophus

15 <400> 10

Met Ala Leu Gly Met Leu Thr Gly Ser Leu Val Ala Ile Val Thr Pro  
 1 5 10 15

20 Met Phe Glu Asp Gly Arg Leu Asp Leu Asp Ala Leu Lys Lys Leu Val  
 20 25 30

Asp Phe His Val Glu Ala Gly Thr Asp Gly Ile Val Ile Val Gly Thr  
 35 40 45

25 Thr Gly Glu Ser Pro Thr Val Asp Val Asp Glu His Cys Leu Leu Ile  
 50 55 60

Lys Thr Thr Ile Glu His Val Ala Lys Arg Val Pro Val Ile Ala Gly  
 65 70 75 80

30 Thr Gly Ala Asn Ser Thr Ala Glu Ala Ile Glu Leu Thr Ala Lys Ala  
 85 90 95

35 Lys Ala Leu Gly Ala Asp Ala Cys Leu Leu Val Ala Pro Tyr Tyr Asn  
 100 105 110

Lys Pro Ser Gln Glu Gly Leu Tyr Gln His Phe Lys Ala Val Ala Glu  
 115 120 125

40 Ala Val Asp Ile Pro Gln Ile Leu Tyr Asn Val Pro Gly Arg Thr Gly  
 130 135 140

Cys Asp Leu Ser Asn Asp Thr Val Leu Arg Leu Ala Gln Ile Arg Asn  
 145 150 155 160

45 Ile Val Gly Ile Lys Asp Ala Thr Gly Gly Ile Glu Arg Gly Thr Asp  
 165 170 175

Leu Leu Leu Arg Ala Pro Ala Asp Phe Ala Ile Tyr Ser Gly Asp Asp  
 180 185 190

50 Ala Thr Ala Leu Ala Leu Met Leu Leu Gly Gly Lys Gly Val Ile Ser  
 195 200 205

Val Thr Ala Asn Val Ala Pro Lys Leu Met His Glu Met Cys Glu His  
 210 215 220

Ala Leu Asn Gly Asn Leu Ala Ala Ala Lys Ala Ala Asn Ala Lys Leu  
 225 230 235 240  
 5 Phe Ala Leu His Gln Lys Leu Phe Val Glu Ala Asn Pro Ile Pro Val  
 245 250 255  
 Lys Trp Val Leu Gln Gln Met Gly Met Ile Ala Thr Gly Ile Arg Leu  
 10 260 265 270  
 Pro Leu Val Asn Leu Ser Ser Gln Tyr His Glu Val Leu Arg Asn Ala  
 275 280 285  
 15 Met Lys Gln Ala Glu Ile Ala Ala  
 290 295

<210> 11  
 20 <211> 3390  
 <212> DNA  
 <213> Methylophilus methylotrophus

25 <220>  
 <221> CDS  
 <222> (2080)..(2883)

30 <400> 11

```

ccgcaggctcg ctctagagga tcagagttgg acggacaagc tgaagtttg ggagtctgaa 60
gaagctgcgg gcgaagtgtat aaagcagctg aatcaactgt agccactgca agcgacgaaat 120
5 gaaagcaaag ggcgtgcact cgctaaggat gaggcagccg aatctcagaa aaccacgtca 180
gagccgtca aggccgagca agaggtattt ccctcgcca ctgcaacaaa taattcagtt 240
gctgcagcga cattggctga agaagaagtg gttccctaca ttccggaggg ggagtatcag 300
40 gctgcaccca ctccagaaga gatggccaag ggtaatctgg atgtcagtga aaaccagggtt 360
actgaggcta aggcacatcc agtgaatgaa aaggaaatgg ctgcacaaat tgcaagatacg 420
gttggccac cacccgtttt tcagcaggaa ccgtatggcag aaccttattgt agcggctgaa 480
cccgaacccg tattgccacc gccccgtaaaa gccgaaccag ctgtgaagaa tatcacagcg 540
45 ccagtttgttgc cgccggccac tggcgttcgcg gccggcaacca agactgctga atctggatc 600
gttaaatcca aacctgttga tccttaaggct gtggaaagcaa aaaccgtgtt atcaaaaaact 660
gaagtacaaa cacccggggc acaggcacct gctgcggcag cggccgttga agatgacgag 720
50 gtcattccat atattcccgaa aggtgaatat gtggctctgt tcattccatg tgaggccgaa 780
atggttaaag gcaatatggc ggaggcaaat gcacatgcga ctgtatgtca agcgcggccag 840
gtaactgaaa aagggtggc acccacatcg gatgcggcag cagagccatc accgacattt 900
55 gtcgtgtgac aattggcaga accagagccaa gaacctgaat tgccaccggc gcctccggcca 960
tccgtcagca agcctgttgtt gtagagaggtt gcgccagtgg ctgcgtggc agcagaagaa 1020
  
```

## EP 1 188 822 A1

gagaaccag tcgctgcga gcctgagact gagcagccgg ctgccaagg ttttggcct 1080  
 5 gcatcggtcg cctccctgt ggacgcgcca gaagcgccag ctggatgc taaaatcaac 1140  
 caggctgtgg cgccatggc acaagcttgg cgccagcaagg acattaaaaa ctacctcgct 1200  
 gcatatcccc ctgacttcat gccagaaggg ttgccttcca gaaaggcatg ggagtgcaca 1260  
 10 cgcaaacagc gtatctgc aggcagggt gcgattacac tcgtactaaa taatgtgcag 1320  
 attcagcgta acggtaccac tgcgcgtg cagtttgagc aaaaatatgc tgctaaagtt 1380  
 tataaagatg aattggtaa aacactggaa atgcgttacg agccaaacgca gaaacgttgg 1440  
 ttgatcacac gtgaacgtgt tgcccttta accgggttgc cagtagcgag tggccaaacg 1500  
 15 acccgtctgc cagcagtcgc tgccgcgtca tccaaatacgg atgtggtgcg gtcagctgt 1560  
 ccacccgacac aatcgacatc atctgcgcct gtacggaaag tgagtgttgc atcagcgatt 1620  
 gacgccttggg cacaggcttgc ggcagtaaa aacatcaatg cttacttgc ggcgtattct 1680  
 ccagaatttgc tgccggaggg attgccaaac agaggtgtct gggaaacgcgca acgtaaaaag 1740  
 20 cgcttgcggc cacagcaggga caagatcagc ctggatgtca cgaatgttgc cgtgagccgc 1800  
 gaaggagaaa cagcgtggc cacctttagg cagaatatgc cgtctaaggc ctatcgat 1860  
 gaagtagtgcg agcgtctaca gttaaaactg gatgctgcgaa gcaatcgctg gtcgttgc 1920  
 25 cgtgaaagta ccggtagtgc ggcagaagtg ccaatggcga agcagtcgt ggtgcgcaca 1980  
 gaagagagatc cggaaacatca ggtatgtct ctggagccgc tggattttatggatgt 2040  
 gatgtcgtaa tttaagtatt aaaaataatt gatgtgaggatg ttg aaa gta gtg 2094  
 Met Leu Lys Val Val  
 30 1 5  
 att gct ggc gtg tct ggt cgt atg gga cat gcc tta ctg gat gga gtt 2142  
 Ile Ala Gly Val Ser Gly Arg Met Gly His Ala Leu Leu Asp Gly Val  
 10 15 20  
 35 ttt tct gat aac ggc ttg cag ttg cac gcg gca ctc gat cgt gct gaa 2190  
 Phe Ser Asp Asn Gly Leu Gln Leu His Ala Ala Leu Asp Arg Ala Glu  
 25 30 35  
 40 agc gcc atg ata ggg cgg gat gca ggc gag cag ttt ggc aag gtc agt 2238  
 Ser Ala Met Ile Gly Arg Asp Ala Gly Glu Gln Phe Gly Lys Val Ser  
 45 40 45 50  
 ggc gtg aaa atc acg gct gac atc cat gcc gca ttg gtc ggt gcc gat 2286  
 Gly Val Lys Ile Thr Ala Asp Ile His Ala Ala Leu Val Gly Ala Asp  
 50 55 60 65  
 45 gtg ctg gtg gat ttc acg cgg ccg gaa gcc agt atg caa tat tta caa 2334  
 Val Leu Val Asp Phe Thr Arg Pro Glu Ala Ser Met Gln Tyr Leu Gln  
 55 70 75 80 85  
 50 gcc tgc cag caa gcc aac gtt aaa tta gtg att ggt act acc ggg ttt 2382  
 Ala Cys Gln Gln Ala Asn Val Lys Leu Val Ile Gly Thr Thr Gly Phe  
 55 90 95 100

## EP 1 188 822 A1

agt gag gca gaa aag gcc agt att gag gct gcg tcc aaa aat atc ggt 2430  
 Ser Glu Ala Glu Lys Ala Ser Ile Glu Ala Ala Ser Lys Asn Ile Gly  
 105 110 115  
 atc gta ttt gct cca aac atg agc gta ggg gtc acc ctc ttg att aac 2478  
 Ile Val Phe Ala Pro Asn Met Ser Val Gly Val Thr Leu Leu Ile Asn  
 120 125 130  
 ctg gtt gag caa gcc gca cg<sup>g</sup> gtg ctc aat gaa ggc tat gat att gag 2526  
 Leu Val Glu Gln Ala Ala Arg Val Leu Asn Glu Gly Tyr Asp Ile Glu  
 135 140 145  
 gtg gtt gaa atg cat cac cg<sup>c</sup> cat aag gtg gat g<sup>c</sup> g<sup>c</sup> c<sup>t</sup> tca g<sup>c</sup> ac<sup>g</sup> 2574  
 Val Val Glu Met His His Arg His Lys Val Asp Ala Pro Ser Gly Thr  
 150 155 160 165  
 gct tta cg<sup>g</sup> ttg ggt gag gct g<sup>c</sup> g<sup>c</sup> aaa ggg att gat aaa g<sup>c</sup> g<sup>c</sup> ctt 2622  
 Ala Leu Arg Leu Gly Glu Ala Ala Lys Gly Ile Asp Lys Ala Leu  
 170 175 180  
 aaa gat tgt gct gtg tat g<sup>c</sup> g<sup>c</sup> gaa g<sup>c</sup> g<sup>c</sup> gtg act ggt gaa c<sup>c</sup> g<sup>c</sup> gaa 2670  
 Lys Asp Cys Ala Val Tyr Ala Arg Glu Gly Val Thr Gly Glu Arg Glu  
 185 190 195  
 g<sup>c</sup> g<sup>c</sup> ac<sup>g</sup> att ggt ttt g<sup>c</sup> a<sup>c</sup> t<sup>t</sup> a<sup>c</sup> c<sup>t</sup> g<sup>t</sup> g<sup>t</sup> g<sup>c</sup> g<sup>t</sup> g<sup>c</sup> g<sup>t</sup> 2718  
 Ala Gly Thr Ile Gly Phe Ala Thr Leu Arg Gly Gly Asp Val Val Gly  
 200 205 210  
 gac cat acg gtg gtt ctg gct ggt gtg ggt gag cga gta gag tta ac<sup>g</sup> 2766  
 Asp His Thr Val Val Leu Ala Gly Val Gly Glu Arg Val Glu Leu Thr  
 215 220 225  
 cat aaa gca tca agc cgt gcc aca ttt gca caa ggt g<sup>c</sup> g<sup>c</sup> tta cgt g<sup>c</sup> 2814  
 His Lys Ala Ser Ser Arg Ala Thr Phe Ala Gln Gly Ala Leu Arg Ala  
 230 235 240 245  
 gct aaa ttt ctg gct gat aaa ccc aag gga ttg ttt gat atg cgt gat 2862  
 Ala Lys Phe Leu Ala Asp Lys Pro Lys Gly Leu Phe Asp Met Arg Asp  
 250 255 260  
 gtg ttg gga ttt gaa aag aac tgatcttag taggcgatcc cgtctggcta 2913  
 Val Leu Gly Phe Glu Lys Asn  
 265  
 aggtctggca ggaatcgctc gatgc<sup>t</sup>ctg agttgccctt gagtg<sup>gg</sup>ctg tcaatgtacg 2973  
 50 ctataatgtc gtaattctga aacggagaaga gtcgaacaag cttttcccgt tttcacate 3033  
 tattcactgc agcttgaatt tcacttccag ccattggtaaa ccctctaaaa gatgtgttcc 3093  
 gtgtcaaact taaggagcta aagggtcaa aaacaattcc agcgattctc gtgttagcag 3153  
 atgaaactgt tttaaggc attagcatgg ggccttccgg tcatacgta ggtgaggtgg 3213

5 tggtaatac ctccatcacc gtttatcagg agattcttac cgatcccttc tataccgaac 3273  
 aaatcggtac actgacctat ccgcacattg gtaactacgg gaccaatcggt gaagatggga 3333  
 gtcaggtaaa gtctatgctg cgggtctgat ccccggtacc gagccgggtt cgtaaag 3390

10 <210> 12

<211> 268

<212> PRT

<213> Methylophilus methylotrophus

15 <400> 12

Met Leu Lys Val Val Ile Ala Gly Val Ser Gly Arg Met Gly His Ala

1 5 10 15

20 Leu Leu Asp Gly Val Phe Ser Asp Asn Gly Leu Gln Leu His Ala Ala

20 25 30

Leu Asp Arg Ala Glu Ser Ala Met Ile Gly Arg Asp Ala Gly Glu Gln

35 40 45

25 Phe Gly Lys Val Ser Gly Val Lys Ile Thr Ala Asp Ile His Ala Ala

50 55 60

Leu Val Gly Ala Asp Val Leu Val Asp Phe Thr Arg Pro Glu Ala Ser

30 65 70 75 80

Met Gln Tyr Leu Gln Ala Cys Gln Gln Ala Asn Val Lys Leu Val Ile

85 90 95

35 Gly Thr Thr Gly Phe Ser Glu Ala Glu Lys Ala Ser Ile Glu Ala Ala

100 105 110

Ser Lys Asn Ile Gly Ile Val Phe Ala Pro Asn Met Ser Val Gly Val

115 120 125

40 Thr Leu Leu Ile Asn Leu Val Glu Gln Ala Ala Arg Val Leu Asn Glu

130 135 140

Gly Tyr Asp Ile Glu Val Val Glu Met His His Arg His Lys Val Asp

45 145 150 155 160

Ala Pro Ser Gly Thr Ala Leu Arg Leu Gly Glu Ala Ala Ala Lys Gly

165 170 175

Ile Asp Lys Ala Leu Lys Asp Cys Ala Val Tyr Ala Arg Glu Gly Val

180 185 190

50 Thr Gly Glu Arg Glu Ala Gly Thr Ile Gly Phe Ala Thr Leu Arg Gly

195 200 205

Gly Asp Val Val Gly Asp His Thr Val Val Leu Ala Gly Val Gly Glu

55 210 215 220

Arg Val Glu Leu Thr His Lys Ala Ser Ser Arg Ala Thr Phe Ala Gln  
 225 230 235 240  
 5 Gly Ala Leu Arg Ala Ala Lys Phe Leu Ala Asp Lys Pro Lys Gly Leu  
 245 250 255  
 Phe Asp Met Arg Asp Val Leu Gly Phe Glu Lys Asn  
 10 260 265

<210> 13  
 <211> 2566  
 15 <212> DNA  
 <213> *Methylophilus methylotrophus*

20 <220>  
 <221> CDS  
 <222> (751)..(1995)

25 <400> 13  
 tgcttttaggg ggaacctaga ggatccccct acccgaggaa gaagtgagcc aacatgtact 60  
 tccagtcgt a ccatcaaaaag tagaagttt cggcggttatac ctgattcaca gtaaacgaaa 120  
 aattgcctat attctgaccg gatttacgg tggctttaa ggtataagtg gtcgctgact 180  
 ggttctcaat gctgtaatca aaaaatttgg catcactggg gacacaggca aatcccacat 240  
 atgtgaagtt gtctgtataa aactgttccgg cctgcacacg gcaattggca agattggcag 300  
 gcgcgttccgc ggcattaccg ctttgatgt aatcctgata gcctggatg gcgatgctgg 360  
 30 ccaagatacc cataatggcc accacgacca tgactttat caggctgaat ccgtactgat 420  
 ttgaggactt cattatcaaa cccctttta gatagcctta tcatgcaaac aggcaagctgt 480  
 35 catgtccagc atcagccgac caatggtag gattaccgca cgaacggta aaccactaaa 540  
 acggccagtc actggtgcca tgagcaactg caggttaat gataaaatgg cactcaattt 600  
 acattggact gtgaacatgt ttcccttcta tacgagatta ttggcggttg ccctgctatt 660  
 ggcacaattt agtgcctgtg gtctcaaagg ggacctgtat attcctgagc gccaataaccc 720  
 tcaaacgcct caacaagata agtcttcatc gtg acc gct ttt tca atc caa caa 774

45 Val Thr Ala Phe Ser Ile Gln Gln

1 5

50 ggc cta cta cat gcc gag aat gta gca ctg cgt gac att gca caa acg 822  
 Gly Leu Leu His Ala Glu Asn Val Ala Leu Arg Asp Ile Ala Gln Thr

55 10 15 20  
 cat caa acg ccc act tac gtc tat tca cgt gcc gca ttg acg act gct 870  
 His Gln Thr Pro Thr Tyr Val Tyr Ser Arg Ala Ala Leu Thr Thr Ala  
 25 30 35 40

## EP 1 188 822 A1

|   |      |
|---|------|
| ttc gag cgt ttt cag gca ggc ctg act gga cat gac cat ttg atc tgc | 918  |
| Phe Glu Arg Phe Gln Ala Gly Leu Thr Gly His Asp His Leu Ile Cys |      |
| 5 45 50 55  |      |
| ttt gct gtc aaa gcc aac cca agc ctg gcc att ctc aac ctg ttt gcg | 966  |
| Phe Ala Val Lys Ala Asn Pro Ser Leu Ala Ile Leu Asn Leu Phe Ala |      |
| 10 60 65 70   |      |
| cga atg gga ggc ggc ttt gat att gtg tcc ggt ggt gag ctg gca cgc | 1014 |
| Arg Met Gly Ala Gly Phe Asp Ile Val Ser Gly Gly Glu Leu Ala Arg |      |
| 15 75 80 85   |      |
| gtc ttg gcc gca ggt ggc gac ccg aaa aaa gtg gtg ttt tct ggt gtg | 1062 |
| Val Leu Ala Ala Gly Gly Asp Pro Lys Lys Val Val Phe Ser Gly Val |      |
| 20 90 95 100  |      |
| gac aaa tcc cat gcg gaa atc aaa gcc gcg ctt gaa gcg ggc att ctt | 1110 |
| Gly Lys Ser His Ala Glu Ile Lys Ala Ala Leu Glu Ala Gly Ile Leu |      |
| 105 110 115 120   |      |
| tgc ttc aac gtg gaa tca gtg aat gag cta gac cgc atc cag cag gtg | 1158 |
| Cys Phe Asn Val Glu Ser Val Asn Glu Leu Asp Arg Ile Gln Gln Val |      |
| 25 125 130 135  |      |
| gcg gcc agc ctg ggc aaa aaa gcg cct att tcc ctg cgc gtg aac ccc | 1206 |
| Ala Ala Ser Leu Gly Lys Ala Pro Ile Ser Leu Arg Val Asn Pro     |      |
| 30 140 145 150  |      |
| aat gtg gat gcc aaa aca cat ccc tat att tcc cac ccg get ctc aaa | 1254 |
| Asn Val Asp Ala Lys Thr His Pro Tyr Ile Ser His Pro Ala Leu Lys |      |
| 35 155 160 165  |      |
| aac aat aaa ttt ggt gtg gca ttt gaa gat gcc ttg ggc ctc tat gaa | 1302 |
| Asn Asn Lys Phe Gly Val Ala Phe Glu Asp Ala Leu Gly Leu Tyr Glu |      |
| 40 170 175 180  |      |
| aaa gcg gcg caa ctg cca aac atc gag gta cac ggc gta gat tgc cat | 1350 |
| Lys Ala Ala Gln Leu Pro Asn Ile Glu Val His Gly Val Asp Cys His |      |
| 185 190 195 200   |      |
| atc ggc tcg caa atc act gag ctg tca cct ttc ctc gat gcc ttg gat | 1398 |
| Ile Gly Ser Gln Ile Thr Glu Leu Ser Pro Phe Leu Asp Ala Leu Asp |      |
| 45 205 210 215  |      |
| aaa gta ttg ggc ctg gta gat gca ttg gcc gcc aaa ggc att cat atc | 1446 |
| Lys Val Leu Gly Leu Val Asp Ala Leu Ala Lys Gly Ile His Ile     |      |
| 50 220 225 230  |      |
| cag cat ata gac gtt ggc ggc ggt gtc ggt att act tac agc gac gaa | 1494 |
| Gln His Ile Asp Val Gly Gly Val Gly Ile Thr Tyr Ser Asp Glu     |      |

## EP 1 188 822 A1

|    | 235  | 240 | 245 |      |
|----|--|-----|-----|------|
| 5  | acg cca cca gac ttt gca gcc tac act gca gcg att ctt aaa aag ctg<br>Thr Pro Pro Asp Phe Ala Ala Tyr Thr Ala Ala Ile Leu Lys Lys Leu   |     |     | 1542 |
|    | 250  | 255 | 260 |      |
| 10 | gca ggc agg aat gta aaa gtg ttg ttt gag ccc ggc cgt gcc ctg gtg<br>Ala Gly Arg Asn Val Lys Val Leu Phe Glu Pro Gly Arg Ala Leu Val   |     |     | 1590 |
|    | 265  | 270 | 275 | 280  |
| 15 | ggt aac gcc ggt gtg ctg ctg acc aag gtc gaa tac ctg aaa cct ggc<br>Gly Asn Ala Gly Val Leu Leu Thr Lys Val Glu Tyr Leu Lys Pro Gly   |     |     | 1638 |
|    | 285  | 290 | 295 |      |
| 20 | gaa acc aaa aac ttt gcg att gtc gat gcc gcc atg aac gac ctc atg<br>Glu Thr Lys Asn Phe Ala Ile Val Asp Ala Ala Met Asn Asp Leu Met   |     |     | 1686 |
|    | 300  | 305 | 310 |      |
| 25 | cgc ccg gct ttg tat gat gct ttc cac aac att acg acc att gcc act<br>Arg Pro Ala Leu Tyr Asp Ala Phe His Asn Ile Thr Thr Ile Ala Thr   |     |     | 1734 |
|    | 315  | 320 | 325 |      |
| 30 | tct gca gcc ccc gca caa atc tat gag atc gtt ggc ccg gtt tgc gag<br>Ser Ala Ala Pro Ala Gln Ile Tyr Glu Ile Val Gly Pro Val Cys Glu   |     |     | 1782 |
|    | 330  | 335 | 340 |      |
| 35 | agt ggt gac ttt tta ggc cat gac cgt aca ctt gcg atc gaa gaa ggt<br>Ser Gly Asp Phe Leu Gly His Asp Arg Thr Leu Ala Ile Glu Glu Gly   |     |     | 1830 |
|    | 345  | 350 | 355 | 360  |
| 40 | gat tac ctg gcg att cac tcc gca ggc gct tat ggc atg agc atg gcc<br>Asp Tyr Leu Ala Ile His Ser Ala Gly Ala Tyr Gly Met Ser Met Ala   |     |     | 1878 |
|    | 365  | 370 | 375 |      |
| 45 | agc aac tac aac acg cgc gcc cgt gcc gca gag gta ttg gtt gat ggt<br>Ser Asn Tyr Asn Thr Arg Ala Arg Ala Glu Val Leu Val Asp Gly   |     |     | 1926 |
|    | 380  | 385 | 390 |      |
| 50 | gac cag gtg cat gtg atc cgt gaa cgt gaa caa att gcc gac ctg ttt<br>Asp Gln Val His Val Ile Arg Glu Arg Glu Gln Ile Ala Asp Leu Phe   |     |     | 1974 |
|    | 395  | 400 | 405 |      |
| 55 | aaa ctg gag cgt acg ctg cca taacattgac ggcaaccct aataaaaaaa<br>Lys Leu Glu Arg Thr Leu Pro   |     |     | 2025 |
|    | 410  | 415 |     |      |
|    | ccgaaggccgc caagcttcgg ttttttatta atagcgcatc cttaatcaa agatcacgtt 2085<br>cttgttcgctg tagagcaaga ttctatgctc aatatgccag cgcacggctt tggaaagcac 2145<br>aacacgctcc aggtcacggc ctttctggat caggtcttcc acctgatcgc ggtgtgaard 2205<br>gcgcgccaaag tcctgctcaa taatcgcccc ctcatccaac acctctgtca cataatgact 2265 |     |     |      |

5  
aaatgctggc aggaatgagt ggtggtaat cgctgaggat accgtgcac 2385  
aaaatcttgt gacagaatct gcatgttagcg tgccagcaca atcaggtaa tcttgtttg 2445  
atcaaacagg gcaaactgct gngcctctac ctctgccttg gtttaccttgc 2505  
aatagtaaaa cggatgccaa taaaactgct ccaggggat cctctggtc cccctaaagc 2565  
a 2566

10 <210> 14

15 <211> 415

<212> PRT

<213> *Methylophilus methylotrophus*

20 <400> 14

Val Thr Ala Phe Ser Ile Gln Gln Gly Leu Leu His Ala Glu Asn Val

1 5 10 15

Ala Leu Arg Asp Ile Ala Gln Thr His Gln Thr Pro Thr Tyr Val Tyr

25 20 25 30

Ser Arg Ala Ala Leu Thr Thr Ala Phe Glu Arg Phe Gln Ala Gly Leu

35 35 40 45

Thr Gly His Asp His Leu Ile Cys Phe Ala Val Lys Ala Asn Pro Ser

50 55 60

Leu Ala Ile Leu Asn Leu Phe Ala Arg Met Gly Ala Gly Phe Asp Ile

65 65 70 75 80

Val Ser Gly Gly Glu Leu Ala Arg Val Leu Ala Ala Gly Gly Asp Pro

85 85 90 95

Lys Lys Val Val Phe Ser Gly Val Gly Lys Ser His Ala Glu Ile Lys

100 100 105 110

Ala Ala Leu Glu Ala Gly Ile Leu Cys Phe Asn Val Glu Ser Val Asn

115 115 120 125

Glu Leu Asp Arg Ile Gln Gln Val Ala Ala Ser Leu Gly Lys Lys Ala

130 130 135 140

Pro Ile Ser Leu Arg Val Asn Pro Asn Val Asp Ala Lys Thr His Pro

145 145 150 155 160

Tyr Ile Ser His Pro Ala Leu Lys Asn Asn Lys Phe Gly Val Ala Phe

165 165 170 175

Glu Asp Ala Leu Gly Leu Tyr Glu Lys Ala Ala Gln Leu Pro Asn Ile

180 180 185 190

Glu Val His Gly Val Asp Cys His Ile Gly Ser Gln Ile Thr Glu Leu

|    |   |     |     |
|----|---|-----|-----|
|    | 195   | 200 | 205 |
| 5  | Ser Pro Phe Leu Asp Ala Leu Asp Lys Val Leu Gly Leu Val Asp Ala |     |     |
|    | 210   | 215 | 220 |
|    | Leu Ala Ala Lys Gly Ile His Ile Gln His Ile Asp Val Gly Gly Gly |     |     |
|    | 225   | 230 | 235 |
| 10 | Val Gly Ile Thr Tyr Ser Asp Glu Thr Pro Pro Asp Phe Ala Ala Tyr |     | 240 |
|    | 245   | 250 | 255 |
|    | Thr Ala Ala Ile Leu Lys Lys Leu Ala Gly Arg Asn Val Lys Val Leu |     |     |
|    | 260   | 265 | 270 |
| 15 | Phe Glu Pro Gly Arg Ala Leu Val Gly Asn Ala Gly Val Leu Leu Thr |     |     |
|    | 275   | 280 | 285 |
|    | Lys Val Glu Tyr Leu Lys Pro Gly Glu Thr Lys Asn Phe Ala Ile Val |     |     |
|    | 290   | 295 | 300 |
| 20 | Asp Ala Ala Met Asn Asp Leu Met Arg Pro Ala Leu Tyr Asp Ala Phe |     |     |
|    | 305   | 310 | 315 |
|    | His Asn Ile Thr Thr Ile Ala Thr Ser Ala Ala Pro Ala Gln Ile Tyr |     | 320 |
|    | 325   | 330 | 335 |
| 25 | Glu Ile Val Gly Pro Val Cys Glu Ser Gly Asp Phe Leu Gly His Asp |     |     |
|    | 340   | 345 | 350 |
|    | Arg Thr Leu Ala Ile Glu Glu Gly Asp Tyr Leu Ala Ile His Ser Ala |     |     |
|    | 355   | 360 | 365 |
| 30 | Gly Ala Tyr Gly Met Ser Met Ala Ser Asn Tyr Asn Thr Arg Ala Arg |     |     |
|    | 370   | 375 | 380 |
| 35 | Ala Ala Glu Val Leu Val Asp Gly Asp Gln Val His Val Ile Arg Glu |     |     |
|    | 385   | 390 | 395 |
|    | Arg Glu Gln Ile Ala Asp Leu Phe Lys Leu Glu Arg Thr Leu Pro     |     | 400 |
|    | 405   | 410 | 415 |

40 <210> 15

<211> 39

45 <212> DNA

<213> Artificial Sequence

50 <220>

<223> primer for amilification of tac promoter

55 <400> 15

aggaaattcc ccgttctgga taatgtttt tgcgccgac

EP 1 188 822 A1

5           <210> 16

10          <211> 58

15          <212> DNA

20          <213> Artificial Sequence

25          <220>

30          <223> primer for amplification of tac promoter

35          <400> 16

40          cggatgcattc tagagttAAC ctgcagggtg aaatttttat ccgctcacaa ttccacac   58

45          <210> 17

50          <211> 35

55          <212> DNA

60          <213> Artificial Sequence

65          <220>

70          <223> primer for amplification of dapA\*24 gene

75          <400> 17

80          tgacctgcag gtttgcacag aggtatggccc atgtt                           35

85          <210> 18

90          <211> 36

95          <212> DNA

100         <213> Artificial Sequence

105         <220>

110         <223> primer for amplification of dapA\*24 gene

115         <400> 18

120         cattcttagat ccctaaactt tacagcaaac cggcat                           36

125         <210> 19

130         <211> 35

135         <212> DNA

140         <213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; primer for amplification of lysC\*80 gene

5

&lt;400&gt; 19

gaacctgcag gccctgacac gaggttagatt atgtc

35

10

&lt;210&gt; 20

&lt;211&gt; 55

15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

20

&lt;223&gt; primer for amplification of lysC\*80 gene

&lt;400&gt; 20

25

ctttcggtta gaagagcgag atgcagataa aaaaattaaa ggcaattatt ctccg

55

## 30 Claims

1. A *Methylophilus* bacterium having L-amino acid-producing ability.
2. The *Methylophilus* bacterium according to claim 1, wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.
3. The *Methylophilus* bacterium according to claim 1, which shows resistance to an L-amino acid analogue or L-amino acid auxotrophy.
4. The *Methylophilus* bacterium according to claim 1, wherein L-amino acid biosynthetic enzyme activity is enhanced.
5. The *Methylophilus* bacterium according to claim 1, wherein dihydrodipicolinate synthase activity and aspartokinase activity are enhanced, and the bacterium has L-lysine-producing ability.
6. The *Methylophilus* bacterium according to claim 1, wherein dihydrodipicolinate synthase activity is enhanced, and the bacterium has L-lysine-producing ability.
7. The *Methylophilus* bacterium according to claim 1, wherein aspartokinase activity is enhanced, and the bacterium has L-lysine-producing ability.
8. The *Methylophilus* bacterium according to any one of claims 5 to 7, wherein an activity or activities of one, two or three of enzymes selected from aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate reductase and diaminopimelate decarboxylase is/are enhanced.
- 50 9. The *Methylophilus* bacterium according to claim 5, wherein the dihydrodipicolinate synthase activity and the aspartokinase activity are enhanced by transformation through introduction into cells, of a DNA coding for dihydrodipicolinate synthase that does not suffer feedback inhibition by L-lysine and a DNA coding for aspartokinase that does not suffer feedback inhibition by L-lysine.

**EP 1 188 822 A1**

10. The *Methylophilus* bacterium according to claim 1, wherein activities of aspartokinase, homoserine dehydrogenase, homoserine kinase and threonine synthase are enhanced, and the bacterium has L-threonine-producing ability.
- 5 11. The bacterium according to any one of claims 1 to 10, wherein the *Methylophilus* bacterium is *Methylophilus methylotrophicus*.
- 10 12. A method for producing an L-amino acid, which comprises culturing a *Methylophilus* bacterium as defined in any one of claim 1 to 11 in a medium to produce and accumulate an L-amino acid in culture and collecting the L-amino acid from the culture.
13. The method according to claim 12, wherein the medium contains methanol as a main carbon source.
- 15 14. A method for producing bacterial cells of a *Methylophilus* bacterium with an increased content of an L-amino acid, which comprises culturing a *Methylophilus* bacterium as defined in any one of claim 1 to 11 in a medium to produce and accumulate an L-amino acid in bacterial cells of the bacterium.
- 20 15. The method for producing bacterial cells of the *Methylophilus* bacterium according to claim 14, wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.
- 25 16. A DNA which codes for a protein defined in the following (A) or (B):  
(A) a protein which has the amino acid sequence of SEQ ID NO: 6, or  
(B) a protein which has an amino acid sequences of SEQ ID NO: 6 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has aspartokinase activity.
- 30 17. The DNA according to claim 16, which is a DNA defined in the following (a) or (b):  
(a) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5; or  
(b) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5 or a part thereof under a stringent condition, and codes for a protein having aspartokinase activity.
- 35 18. A DNA which codes for a protein defined in the following (C) or (D):  
(C) a protein which has the amino acid sequence of SEQ ID NO: 8, or  
(D) a protein which has an amino acid sequences of SEQ ID NO: 8 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has aspartic acid semialdehyde dehydrogenase activity.
- 40 19. The DNA according to claim 18, which is a DNA defined in the following (c) or (d):  
(c) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7; or  
(d) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7 or a part thereof under a stringent condition, and codes for a protein having aspartic acid semialdehyde dehydrogenase activity.
- 45 20. A DNA which codes for a protein defined in the following (E) or (F):  
(E) a protein which has the amino acid sequence of SEQ ID NO: 10, or  
(F) a protein which has an amino acid sequences of SEQ ID NO: 10 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydrodipicolinate synthase activity.
- 50 21. The DNA according to claim 20, which is a DNA defined in the following (e) or (f):  
(e) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers

**EP 1 188 822 A1**

1268 to 2155 of SEQ ID NO: 9; or

(f) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 1268 to 2155 of SEQ ID NO: 9 or a part thereof under a stringent condition, and codes for a protein having dihydronicotinate synthase activity.

5

**22.** A DNA which codes for a protein defined in the following (G) or (H):

(G) a protein which has the amino acid sequence of SEQ ID NO: 12, or

(H) a protein which has an amino acid sequences of SEQ ID NO: 12 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydronicotinate reductase activity.

10

**23.** The DNA according to claim 22, which is a DNA defined in the following (g) or (h):

15 (g) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11; or

(h) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11 or a part thereof under a stringent condition, and codes for a protein having dihydronicotinate reductase activity.

20

**24.** A DNA which codes for a protein defined in the following (I) or (J):

(I) a protein which has the amino acid sequence of SEQ ID NO: 14, or

(J) a protein which has an amino acid sequences of SEQ ID NO: 14 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has diaminopimelate decarboxylase activity.

25

**25.** The DNA according to claim 24, which is a DNA defined in the following (i) or (j):

30 (i) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13; or

(j) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13 or a part thereof under a stringent condition, and codes for a protein having diaminopimelate decarboxylase activity.

35

40

45

50

55




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/02295

A. CLASSIFICATION OF SUBJECT MATTER  
Int.Cl' C12N1/21, 1/32, 9/00, 15/52, C12P13/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
Int.Cl' C12N1/20-1/21, 9/00-9/99, 15/52-15/61,  
C12P13/04-13/14

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
GenBank/EMBL/DDBJ/GeneSeq, SwissProt/PIR/GeneSeq,  
WPI (DIALOG), BIOSIS (DIALOG)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| X         | EP, 35831, A2 (IMPERIAL CHEMICAL INDUSTRIES LIMITED), 16 September, 1981 (16.09.81)<br>& NO, 8100773, A & DK, 8100952, A<br>& JP, 56-140893, A & PT, 72630, A<br>& CA, 1187011, A & DE, 3173415, G<br>& RO, 92662, A   | 1,4,11-14             |
| X         | WINDASS, J. D. et al., "Improved conversion of methanol to single-cell protein by Methylophilus methylotrophicus", Nature, October 2, 1980, Volume 287, pp. 396-401  | 1,4,11-14             |
| X         | SCHENDEL, Frederick J. et al., "Cloning and Nucleotide Sequence of the Gene Coding for Aspartokinase II from a Thermophilic Methylotrophic Bacillus sp.", Applied and Environmental Microbiology, September 1992, Volume 58, Number 9, pages 2806-2814<br>GenBank Accession No. M93419 | 17                    |
| X         | HOANG, Tung T. et al., "Molecular genetic analysis of the region containing the essential Pseudomonas aeruginosa and gene encoding aspartate-β-semialdehyde  | 19                    |

 Further documents are listed in the continuation of Box C.  See patent family annex.

|     |   |  |
|-----|---|--|
| *A* | Special categories of cited documents:<br>document defining the general state of the art which is not considered to be of particular relevance                      | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "E" | earlier document but published on or after the international filing date  | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "L" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" | document referring to an oral disclosure, use, exhibition or other means  | "&" document member of the same patent family  |
| "P" | document published prior to the international filing date but later than the priority date claimed  |  |

|   |  |
|---|--|
| Date of the actual completion of the international search<br>05 July, 2000 (05.07.00) | Date of mailing of the international search report<br>18 July, 2000 (18.07.00) |
|---|--|

|  |                    |
|--|--------------------|
| Name and mailing address of the ISA/<br>Japanese Patent Office | Authorized officer |
|--|--------------------|

|               |               |
|---------------|---------------|
| Facsimile No. | Telephone No. |
|---------------|---------------|

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/02295

| C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category*  | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| X  | "dehydrogenase", Microbiology, March 1997, Volume 143, Part 3, pp. 899-907 GenBank Accession No.U11055  |                       |
| X  | YAMAMOTO, Yoshihiro et al., "Construction of a Contiguous 874-kb Sequence of the Escherichia coli-K12 Genome corresponding to 50.5-68.8 min on the Linkage Map and Analysis of Its Sequence Features", DNA Research, April 28, 1997, Volume 4, Number 2, pp.91-113 GenBank Accession No. D90877 | 21                    |
| X  | BONNASSIE, S. et al., "Nucleotide sequence of the dapA gene from Corynebacterium glutamicum", Nucleic Acids Research, November 11, 1990, Volume 18, Number 21, page 6421 GenBank Accession No.X53993  | 21                    |
| X  | BOUVIER, J. et al., "Nucleotide Sequence and Expression of the Escherichia coli dapB Gene", The Journal of Biological Chemistry, December 10, 1984, Volume 259, Number 23, pp.14829-14834 GenBank Accession No. M10611  | 23                    |
| X  | DEKKERS, Linda C. et al., "A site-specific recombinase is required for competitive root colonization by Pseudomonas fluorescens WCS365", Proceedings of the National Academy of Sciences, USA, June 9, 1998, Volume 95, Number 12, pp.7051-7056 GenBank Accession No.Y12268                     | 25                    |
| A  | EP, 37273, A2 (IMPERIAL CHEMICAL INDUSTRIES LIMITED), 07 October, 1981 (07.10.81)<br>& BR, 8101907, A & DK, 8101404, A<br>& JP, 57-8782, A & ZA, 8102086, A<br>& CA, 1187012, A & IL, 62514, A<br>& DE, 3175828, G & KR, 8701127, B   | 1-25                  |
| A  | WO, 96/41871, A1 (Ajinomoto Co., Inc.) 27 December, 1996 (27.12.96)<br>& EP, 834559, A1 & SK, 9701705, A3<br>& CN, 1203629, A & HU, 9900149, A2<br>& US, 5989875, A & MX, 9710044, A1   | 1-25                  |
| A  | Kerney, P. et al., "Regulation and routes of biosynthesis of serine and arginine in Methylophilus methylotrophus ASI", FEMS Microbiology Letters, July 1987, Volume 42, Nos.2-3, pp. 109- 112   | 1-25                  |
| A  | JP, 1-235595, A (Kyowa Hakko Kogyo Co. Ltd.) 20 September, 1989 (20.09.89)<br>(Family: none)  | 1-25                  |
| A  | JP, 53-34987, A (Yoshiki Tani) 31 March, 1978 (31.03.78)  | 1-25                  |

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/02295

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
  
  
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
  
  
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The requirement of unity of invention in international application (PCT Rule 13.1) is not satisfied unless there is a technical relationship in a group of inventions involving one or more of the same or corresponding technical features. The term "technical feature" means a technical feature clearly showing the contribution to the prior art by the inventions as set forth in claims as a whole (PCT Rule 13.2). The requirement of unity of invention is judged without considering whether a group of inventions are described in separate claims or in a single claim in an alternative form (PCT Rule 13.3).

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
  
  
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest  The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/02295

Continuation of Box No. II of continuation of first sheet(1)

Inventions as set forth in claims 1 to 25 have a matter in common of a "bacterium belonging to the genus *Methylophilus* and having an L-amino acid productivity". However, document 1 (Japanese Patent Laid-Open No. 140893/1981) and document 2 (Nature, 287(5781), 396-401 (1980)) describe a bacterium belonging to the genus *Methylophilus* and carrying *Escherichia coli*-origin glutamate dehydrogenase (GDH) gene transferred in a state of allowing the expression thereof. Furthermore, a process for producing an amino acid by culturing this bacterium is stated in document 1 (see, for example, claim 19 and thereafter). As also stated in the description (p. 13) of the present international application, GDH gene is a gene imparting an L-glutamic acid productivity to a bacterium belonging to the genus *Methylophilus*. Therefore, it can be said that the bacterium belonging to the genus *Methylophilus* as described in document 1 or document 2 is a "bacterium belonging to the genus *Methylophilus* and having an L-glutamic acid productivity". Accordingly, there had been publicly known a bacterium belonging to the genus *Methylophilus* and having a productivity of l-glutamic acid, i.e., one of L-amino acids. Thus, the "bacterium belonging to the genus *Methylophilus* and having an L-amino acid productivity" which is the matter common to inventions as set forth in claims 1 to 25 cannot be regarded as a "special technical feature" as defined in PCT Rule 13.2.

Also, there had been publicly known a dihydrodipicolinate synthase gene (i.e., a gene capable of imparting an L-lysine productivity to a bacterium belonging to the genus *Methylophilus*) originating in a bacterium belonging to the genus *Corynebacterium* (see, for example, document 3 (Nucleic Acids Res., 18(21), 6421 (1990))). Accordingly, the "special technical feature" common to inventions as set forth in claims 16 to 25 is not an "enzyme gene being usable in enhancing the L-lysine productivity of a bacterium belonging to the genus *Methylophilus*" but an "enzyme gene originating in a bacterium belonging to the genus *Methylophilus* and being usable in enhancing the L-lysine productivity of a bacterium belonging to the genus *Methylophilus*". Thus, it may be said that there is no "special technical feature" as defined in PCT Rule 13.2 between the group of inventions as set forth in claims 1 to 15 relating to a bacterium belonging to the genus *Methylophilus* and having an L-lysine productivity and the group of inventions as set forth in claims 16 to 25.

Such being the case, the claims involve the following six groups of inventions:

- ① inventions relating to a bacterium belonging to the genus *Methylophilus* and having an L-lysine productivity as set forth in claims 1 to 15;
- ② inventions relating to a bacterium belonging to the genus *Methylophilus* and having an L-valine productivity as set forth in claims 1 to 15;
- ③ inventions relating to a bacterium belonging to the genus *Methylophilus* and having an L-leucine productivity as set forth in claims 1 to 15;
- ④ inventions relating to a bacterium belonging to the genus *Methylophilus* and having an L-isoleucine productivity as set forth in claims 1 to 15;
- ⑤ inventions relating to a bacterium belonging to the genus *Methylophilus* and having an L-threonine productivity as set forth in claims 1 to 15; and
- ⑥ inventions as set forth in claims 16 to 25.

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**